Published in final edited form as:

Adv Drug Deliv Rev. 2014 April 20; 0: 52–66. doi:10.1016/j.addr.2013.11.010.

Miniaturized pre-clinical cancer models as research and diagnostic tools

Maria Håkanson¹, Edna Cukierman^{2,*}, and Mirren Charnley^{3,*}

¹CSEM SA, Section for Micro-Diagnostics, 7302 Landquart, Switzerland ²Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA 19111, US ³Centre for Micro-Photonics and Industrial Research Institute Swinburne, Swinburne University of Technology, Victoria 3122, Australia

Abstract

Cancer is one of the most common causes of death worldwide. Consequently, important resources are directed towards bettering treatments and outcomes. Cancer is difficult to treat due to its heterogeneity, plasticity and frequent drug resistance. New treatment strategies should strive for personalized approaches. These should target neoplastic and/or activated microenvironmental heterogeneity and plasticity without triggering resistance and spare host cells. In this review, the putative use of increasingly physiologically relevant microfabricated cell-culturing systems intended for drug development is discussed. There are two main reasons for the use of miniaturized systems. First, scaling down model size allows for high control of microenvironmental cues enabling more predictive outcomes. Second, miniaturization reduces reagent consumption, thus facilitating combinatorial approaches with little effort and enables the application of scarce materials, such as patient-derived samples. This review aims to give an overview of the state-of-the-art of such systems while predicting their application in cancer drug development.

Keywords

Microfluidics; cancer models; pre-clinical drug assessment; cell culturing devices; extracellular matrix; microfabricated model systems; tumor microenvironment; cell adhesion-mediated drug resistance; combinatorial screening platforms; body-on-a-chip

© 2013 Elsevier B.V. All rights reserved.

*corresponding authors: To handle correspondence at all stages contact: Edna Cukierman, Cancer Biology/Fox Chase Cancer Center, 333 Cottman Avenue W428, Philadelphia PA 19111, USA, +1(215)-214-4218, Edna.Cukierman@FCCC.edu Or Mirren Charnley, Centre for Micro-Photonics and Industrial Research Institute Swinburne, Faculty of Engineering & Industrial Sciences (H34), Swinburne University of Technology, John street, Hawthorn, Victoria, 3122, Australia, +61 3 9214 8008, mcharnley@swin.edu.au.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

Cancer remains a leading cause of death, for example, it is predicted to be responsible for one of every four deaths in the United States for 2013 [1]. Thus, it is not surprising that the majority of drug candidates in development today are aimed at stalling or eliminating cancer [2]. However, cancer drug development is costly, as it suffers from a very low success rate. For new compounds in clinical development, the success rate is three times lower for cancer drugs than for drugs treating cardiovascular diseases [3]. Several factors complicate the development of drugs that can effectively treat cancer. The high heterogeneity and plasticity of an ever-changing dynamic disease [4] makes it difficult to develop drugs that are widely applicable and that have low side-effects. Resistance to treatment ensues due to both repetitive treatment [5] and the unique cues derived from the tumor-specific microenvironment. Development of more specific drugs, which are less likely to induce resistance, requires not only smart drug design but also more predictive pre-clinical tests [6, 7]. Together with the development of personalized approaches, treatments specifically targeting the interaction between cancer cells and tumor-associated microenvironment may enable us to overcome the hurdle posed by the heterogeneity in cancer [8–10].

There is extensive evidence demonstrating the importance of the tumor microenvironment on cancer progression [11–13] and treatment outcome [14, 15]. In fact, the tumor-associated stroma can play a role as a pro-tumorigenic environment [16], a drug desensitization setting [6, 17–19] or a drug penetration barrier [20–22], which complicates any therapeutic approach. To this end, the specific cross talk between a given cancer and its stroma will have to be defined for each cancer type (and perhaps for each patient) in order to achieve effective therapeutic targeting [23]. Consequently, *in vitro* models that better reflect the *in vivo* environment may provide a more accurate indication of patient outcome [24–27]. The parameters that are critical for a functional model have been studied in-depth (Fig. 1). For example, culture of cells in a 3D environment is crucial for several aspects of cell behavior [28–30] including the regulation of growth in cancerous [31–33] and migratory cells [13, 34, 35] as well as for cell-cell interaction-dependent processes such as morphogenesis [32, 36]. More relevant culture systems not only include adapting the culture environment but also require advances in the types of cells that are used. Established and immortalized cell lines are typically applied due to their ease of use, reproducibility, and availability. However, many of these cell lines are often altered in comparison to the corresponding primary cells or original tumors on both a phenotypic and genotypic level [37]. Therefore, moving to the use of primary cells (although often not very practical) is one way of increasing predictivity of *in vitro* assays [38, 39]. However, due to the high level of heterogeneity in neoplasias resulting in differing drug responses even between patients with the same diagnosis, it may sometimes be necessary to use patient-derived cells to ensure a higher level of *in vivo* mimicry and hence increase the predictive value of personalized assays [40, 41]. As heterotypic cell interactions are very fundamental for the function of certain tissues [42], co-culture methods including multiple cell types per model system is another means of increasing relevance [43–45].

Today there are a vast number of approaches, using microfabrication and novel scaffolds materials, to develop new (i.e., 3D) cell culture platforms that recapitulate the characteristics

of the *in vivo* environment [13, 44, 46–52]. These models have been crucial for the understanding of the role of the *in vivo* environment on the behavior of normal and malignant cells [53] and are currently making the first steps into drug development [54]. Microfabricated culture systems are advantageous as they offer control of the culture environment with high reproducibility at the level of single cells [55]. Thus a high control of the cell culture environment can be obtained by tightly regulating cell shape, dimensionality, adhesive surfaces/ligands, amount of cell-cell contacts and the level and nature of provided soluble factors [47, 51, 56–58].

Since the early exploration of microfabricated and/or microfluidic systems for cell studies in the 1990s [59], it has been predicted that this research area will contribute to improved systems in drug development [60, 61]. Microtechnological approaches have highlighted the importance of the cell organization on a single-cell level [26, 58, 62], as well as of solute gradients and flow [63–65] for cell behavior and drug response [66]. In spite of a slow translation from the bioengineering labs to the application amongst biologists and clinical researchers, the motivation to improve the *in vitro* tools in pre-clinical development is now high, providing a greater impetus for new models to be evaluated. More predictive models could cut the costs in drug development, as more compounds could be ruled in or out before conducting expensive animal and patient studies [67]. Clinical trials alone constitute the largest single cost in the drug development process. For the same reason, high-fidelity cell-based assays have been increasingly used in the last decade [68, 69] both in target-validation and pre-clinical screening [70]. The advantage of cell-based over molecular assays is that they better represent the site of action of a drug including more of the *in vivo* complexity. Thereby, unpredicted targets and evidence of possible negative side effects may be discovered at an early stage.

We now stand at a point where the general improvement offered by organotypic cell culture models is widely accepted. However, these models still need to be more extensively evaluated to understand their power in drug development. This is not a trivial task. For example, we need to understand the model complexity needed for a certain disease area. In some instances, increased predictivity in a model may be achieved by simply switching from 2D culture to 3D culture or by replacing established cell lines with primary cells [54]. In other cases, the parallel adaptation of the microenvironment may be crucial for the relevance of other models [32]. To establish this knowledge base, a joint interdisciplinary effort is required involving basic and clinical researchers, bioengineers, pharmacological developers and automation engineers, amongst others. For example, a recent systematic evaluation of different culture techniques at Roche was proven to be efficient at determining the optimal functional models for toxicological studies in hepatocytes [25].

This review aims to highlight the current clinically relevant information that could be obtained using miniaturized (i.e., microfabricated/microfluidics systems) cell models. For example, we will discuss the possibility of mimicking the microenvironment to allow, e.g., stromal-dependent and other heterotypic cell contact-dependent drug responses to be discovered. In general, these systems also offer a unique opportunity for an in-depth mechanistic understanding of specific cellular behaviors crucial in cancer, such as cell transformation and metastasis. In addition, miniaturized models also have great potential in

the field of personalized treatment as diagnostic tools, given the minimal cell numbers needed per sample. Finally, some models will also allow for combinatorial studies of drugs while altering microenvironmental factors, which should be advantageous in the development of targeted personalized strategies [6].

2. The importance of the tumor microenvironment in disease progression and treatment response

Most eukaryotic cells exist in a complex environment in which they are in contact with surrounding cells, soluble factors and/or extracellular matrix (ECM). These interactions are important for the continuous regulation of homeostatic cell dynamics, which is clearly altered during tumor development and progression. There are currently several lines of evidence demonstrating the crucial role of the microenvironment in cancer progression [71], dissemination and metastasis [13, 72]. Hence, even though cancer may originate from genetic mutations, its progression may also be promoted by certain physiological conditions in the cancer microenvironment [73]. In fact, some investigators go as far as to suggest that looking for differences between normal and cancerous cells is unproductive [74], while others suggest treating the activated tumor-microenvironment as a means for cancer erosion [75] or evaluating the levels of stromal activation and using these as predictive factors analogous to classic cancer staging or grading [23, 50, 76]. Although originally proposed more than a century ago [77, 78], the importance of the tumor microenvironment has only recently become well accepted [79–83]. The interaction between cancer cells and their microenvironment reportedly affect the outcome of treatment, [15] and we have only just started to apply this knowledge in diagnosis and treatment [84]. For an improved translation from pre-clinical testing to patient outcome, test models that better reflect the complexity of the cancer microenvironment may become crucial [6, 20, 24].

The vast majority (about 90%) of human cancers are carcinomas, malignant tumors of epithelial origin. For example, the first transformed (cancerous) epithelial cells at the primary site of breast cancer, a common type of carcinoma, are initially surrounded by healthy epithelial cells and by an epithelial cell-derived and laminin rich ECM known as basement membrane. As the tumor progresses, this “normal” basement membrane, that physically separates the epithelial from the connective (mesenchymal) tissue, is degraded thus facilitating a direct interaction (as opposed to indirectly paracrine signaling) between cancer cells and the tumor-associated mesenchymal stroma [85]. With this, the tumor cells are exposed to a changing microenvironment. Initially, the environment contains epithelial cells and predominantly epithelial ECM-associated proteins, such as collagen IV and laminin. Subsequently, the cancer cells directly interact with a completely different niche, the tumor-associated stroma, which is composed of activated mesenchymal cells (e.g., myofibroblasts), which produce and alter collagen I rich ECM with a peculiar topography [13, 80, 86, 87]. Changes also include the stiffening of the tumor stroma by increased collagen deposition and crosslinking [88]. Hence, tumorigenic process itself is thought to be responsible for the activation of the pro-tumorigenic stroma [80, 85]. Reciprocally, it is well accepted that such a tumor-activated mesenchymal microenvironment effectively promotes tumorigenesis in a positive feed-back loop [89, 90]. The activated myofibroblast-rich stroma

has been shown to support cancer progression including cell proliferation and metastasis [91–97]. Parameters that modulate cancer progression include, but are not limited to, integrin signaling [8], matrix rigidity [88], hypoxia [98] and signaling from stromal cells [99]. Interestingly, there is not a clear-cut division in cause and consequence in these tumor-stroma relationships. Moreover, *in vitro* experimentation has shown that, on the one hand, normal fibroblasts (and recruited mesenchymal stem cells as well as others) undergo conversion to myofibroblasts in response to tumor cells [100], but these changes can also be induced as a result of a positive stromal feedback stimulated by the tumor-altered mesenchymal ECMs [87].

In addition to its effects on cancer progression, the microenvironment also alters the overall response to cancer drug treatment [6, 101], for example, by limiting drug penetration through the tumor-associated stroma [20, 102] or by reducing drug effectiveness due to increased cell density and consequently reduced metabolism and proliferation, which lowers the susceptibility of the tumor cells to the drug in question [62, 103]. A more complex factor is the biochemical signaling imparted by the tumor microenvironment known as cell-adhesion mediated drug resistance (CAM-DR) [15, 104]. This drug treatment cancer protective effect originates in the adhesion of cells to both other cells and ECM components at the tumor site (Fig. 2A). The crucial effects of the microenvironment on drug response have been demonstrated in various systems [105]. These include (among others) using cell-derived ECM matrices *in vitro* while validating the observations *in vivo* using animal models and human samples [12, 13, 87, 106]. The interesting observations linking cancer progression with increasing drug resistance were observed in several neoplasias such as ovarian cancer and melanoma. In the first case, a tumor-ECM cooperative effect was found as an over-expression of collagen VI correlated with ovarian cancer grade, while adhesion of tumor cells to this substrate *in vitro* mediated CAM-DR [107]. In the second case, stromal secretion of hepatocyte growth factor (HGF) triggers activation of its receptor MET in melanoma thus reactivating MAPK and PI3K/Akt, which in turn results in an acquired resistance to RAF inhibition [19]. Interestingly, the signaling mechanism responsible for these types of effects comprises a microenvironmental regulated RAF-inhibitor resistance in BRAFV600E mutation. This Ras-independent monomer mutant is insensitive to feedback resulting in a low but constitutive Ras activity. The study suggested to overcome drug resistance through a drug combinational approach using specific RAF and MEK inhibitors resulting in a hindrance of the observed stromal regulated resistance [108].

2.1. Therapeutic strategies targeting the cancer microenvironment

Numerous complex preclinical engineering models [109] and strategies have been developed for the treatment of cancer. The impaired, leaky, vascular system and poor lymphatic drainage of cancerous tissues culminates in an enhanced permeation and retention effect known as the EPR effect [110]. Consequently, cancer drugs coupled to molecules within a certain size range, including macromolecular drugs, liposomes and nanoparticles, are passively targeted to the cancerous tissues [20, 111–113]. Alternatively, markers on the cancerous cells and surrounding vascular tissues are actively targeted through the exploitation of antigen-antibody or ligand-receptor interactions [112–116]. To this end, investigators are actively developing *in vitro* biomimetic platforms/systems [109, 117, 118].

The growing knowledge of the signaling between the microenvironment and cancer cells has resulted in a new therapeutic modality: combinatorial treatments of standard drugs with drugs targeting the microenvironment should be more specific and efficient [6, 15]. Different entities of the cancer microenvironment may be targeted including signaling molecules, such as Hedgehog factor (Hh) [119] and vascular endothelial cells growth factor (VEGF), as well as specific extracellular matrix proteins and integrins. Cell adhesion-mediating integrins and their associated proteins are involved in key signal transduction pathways related to proliferation and survival and may therefore be promising drug targets [120] (Fig. 2B). Integrins have been shown to regulate CAM-DR [105]. In studies of blood cancer, it seemed that leukemic CAM-DR is the result of an integrin-regulated post-transcriptional change, which is caused by degradation of activators of apoptosis such as Bim [121]. Other studies have suggested that hematologic CAM-DR is the result of an increased stability of suppressors of apoptosis and cell cycle regulators [122] and can therefore be directly manipulated.

Studies correlating integrin expression levels in human tumors with pathological outcomes, such as patient survival and metastasis, have identified several integrins that might have an important role in cancer progression. Members of the integrin β_1 family are up-regulated in invasive breast cancer cells where high levels of β_1 -integrin in patient tissue has been correlated to decreased survival [123]. *In vitro* studies revealed the importance of β_1 -integrin for the growth of cancer cells in a 3D Matrigel™ culture while conversely not affecting normal cells [124]. Another report highlighted the importance of $\alpha_3\beta_1$ -integrin in pulmonary metastasis [125], while, in a multiple myeloma animal model, treatment with a $\alpha_4\beta_1$ -integrin blocking antibody effectively disrupted tumor-stromal interactions decreasing tumor burden and increasing apoptosis [126]. In another more recent example, investigators observed similar responses when inhibiting tumor-stromal interactions with cilengitide (EMD 121974), a $\alpha_v\beta_3/\alpha_v\beta_5$ dual integrin inhibitor, compared to docetaxel as second line treatments in non-small cell lung cancer [127]. This trial concluded that there are fewer adverse responses to cilengitide suggesting that these types of drugs could be used in combinatorial drug trials [127]. Furthermore, the combinatorial action of a β_1 -inhibiting antibody with ionizing radiation was much more effective than either of these treatments alone [14]. After years of preclinical studies, there are now several integrin targeting drugs in clinical trials [6, 8, 127]. A particularly promising strategy is based on the interference of integrins expressed during neovascularization with the aim of suppressing tumor-induced stromal angiogenesis. Some trials have been concluded using etaracizumab (also known as Vitaxin, Abegrin or MEDI-522), an antibody against the vitronectin receptor $\alpha_v\beta_3$ -integrin [128–131].

Alternatively, the cancer-specific environment (e.g., vascular system) has also been exploited for the targeted delivery of drug carriers [20, 112, 116, 132] (Fig. 2B), enhancing the efficiency and reducing side effects of drugs. For example, one strategy for the delivery to the tumor tissue is to use a specific gene coupled to a cationic nanoparticle which in turn is coupled to an $\alpha_v\beta_3$ -integrin targeting ligand [133]. A pre-clinical study in mice showed a 15-fold increase in drug efficiency when this method was used to deliver doxorubicin-loaded nanoparticles to integrin $\alpha_v\beta_3$ positive tumor vasculature [9].

The ultimate goal of microenvironment-targeted treatment would be to enable personalized therapy adapted both to the molecular characteristics of the specific cancer and its microenvironment [84]. Personalized treatment, considering both the patient genotype and the stromal phenotype [23, 50, 134–136], is believed to be a solution for improved treatment of this heterogeneous disease. To reach this goal, predictive markers that can be used to determine the optimal treatment for a patient are currently being verified [137, 138]. An important building block in personalized treatment will be relevant biological models that enable the testing of the predictive markers such as tumor grafts in animal models [139]. With the development of miniaturized systems with high physiological relevance, a more pragmatic means of testing patient samples will be made available.

3. Microfabricated model systems for cancer research – possibilities and challenges

3.1. Advantages and disadvantages of microfabricated model system for cancer research

This section describes how microfabricated model systems can be used for cell assays in cancer research. The general advantages and disadvantages of replacing common experimental platforms with microfabricated counterparts are discussed for both open and closed systems. Open systems are defined as microfabricated substrates, for example, 2D adhesive patterns (e.g., stamps), immersed in cell culture media (Fig. 3A), while closed systems consist of microfluidics systems that enable tight control of the culture environment in three dimensions as the liquid volume is controlled and exchanged through inlet and outlet holes (Fig. 3B) [140].

Open systems—Initial research on controlled cell culture platforms focused on the growth of single cells, or cell colonies, on protein patterns of controlled shape and biochemical composition [55]. Thereby the role of cell shape, cell-cell interactions, cell-matrix interaction and even mechanical activation by stretching of the substrates can be specifically assessed. Throughout the years, a large set of technologies to pattern cell culture substrates with adhesive and inert areas in two dimensions have been developed. These technologies typically either rely directly on photolithographic methods or on the cheaper and versatile techniques of soft lithography [141, 142]. The spotting of protein arrays is a complementary technique that can be applied when larger islands are acceptable, i.e., for the patterning of cell colonies. Methods for patterning with high reproducibility and stability over large areas have enabled the industrial production of such platforms [143].

In the booming area of 3D cell culture, microfabricated systems can provide advantages over other types of scaffolds by enabling greater control of, e.g., cell positioning and cluster size. Originally discovered in 1986, 3D Matrigel™ is a commonly used scaffold in organotypic cell culture [144]. This natural material can be tuned for higher control of the culture parameters by structuring the gel into 100µm wide pillars by, for example, the use of soft lithography tools [145]. Seeding single cells onto these pillars reduced size polydispersity of the resultant cell colonies and eased imaging. An alternative approach molded arrays of microwells into the surface of collagen I enabling the creation of microtissues with controlled shape within a day of cell seeding [146]. A drawback of using

ECM-based scaffold materials is that cells may migrate out of cavities. Undesired cell migration can be mitigated by, for example, placing a collagen lid on top of the microwell array. A successful strategy to spatially control the position of microtissues in such an array is to culture cells in microwells surrounded by non-adhesive (i.e., inert) areas. Platforms based on this principle have been extensively investigated in our research group using PDMS microwell arrays [47, 51, 57, 58, 147] and by Lütolf, *et al.* using a microstructured PEG-hydrogel [148], as well as by others. Such platforms provide greater flexibility in the biochemical interface presented to the cells, as the substrate used to fabricate the microwells can be coated with many different proteins. A creative example of how microfabricated 3D model system can enable new studies is the use of magnetic actuated microcantilevers to induce mechanical stress in the microenvironment of hydrogels. The groups of Chen and Reich recently published an elegant study in which they used hydrogels suspended in between an array of flexible columns to assess tissue mechanics. The study successfully separated the mechanical contributions of cell vs. matrices in either static or dynamic loading conditions [149].

One disadvantage of the open format is that it is not always possible to address the individual units in an array. Hence, even though these open cell arrays contain a high number of experimental units with controlled environmental conditions, the full multiplexing potential of the arrays cannot always be fulfilled. To overcome this problem, Lee, *et al.* [150] combined the spotting of drugs on a chip with subsequent stamping onto the cell array. While this approach promises to increase the multiplexing of open systems, there may be issues with the control of the final drug dose and the avoidance of cross-contamination in rinsing steps. Addressability can also be added by directly spotting samples into slightly larger microwells, for example, by using robotic dispensing to spot a large range of plasmid-DNA in a microwell array [151]. After cell seeding, the whole chip is immersed in culture media to ensure enough nutrients and inhibit drying of the sample. Hence, this strategy is only feasible because the DNA was trapped in a denatured protein matrix after spotting; otherwise cross-contamination would occur. In conclusion, multiplexing on a 2D array can be performed when molecules, such as DNA or proteins, can be reliably fixed in the spots. However, the multiplexing of cells or small molecules on these platforms requires further engineering, which could, for example, include the embedding of small drugs into disks of a biodegradable polymer for slow and local diffusion into the immediately adjacent cell culture [152].

Closed systems—Closed systems have the advantage of enabling complete control of the culture environment by means of microfluidic engineering (Fig. 3B). Such systems can be used for cell capture and growth, as well as to perform cell-based assays. A clear advantage is the control of the liquid flow at *in vivo* relevant (capillary) dimensions, which makes it possible to regulate nutrient and drug concentrations at the levels of single cells or small cell clusters [153]. In particular, it is possible to investigate pharmacological responses with very high spatial and temporal control of local drug concentration [154] enabling experiments not possible in bulk. Laminar flow regimes can easily be created in a microchannel and are characterized by low turbulence and mixing of parallel streams by diffusion only. This effect can be utilized both for the loading of cells into wells [155] and for the creation of well-

defined concentration gradients within a given channel [156]. In contrast to open systems, the closed channels make it possible to individually address cells positioned in an array without cross-contamination. This can be obtained by placing several channels in parallel over the substrate or by using laminar flow. The sequential delivery of soluble factors to cells in a complex network of microchannels can be automatically controlled using electric or flow-controlled valves [157].

There is a growing awareness of the difference in cell behavior in 2D versus 3D microenvironments; for example, cell migration differs depending on the dimensionality of the model system [28, 158, 159]. Thus, it is important to develop 3D environments within channels, for example, by filling microchannels with different gel forming materials such as MatrigelTM, collagen or a synthetic peptide-based materials [160, 161]. Thereby the advantages of 3D culture can be combined with the closed system characteristics that allow tight management of soluble factor concentration (i.e., cytokines, chemokines, growth factors, oxygen, levels of acidity and others) as well as controlled flow rates.

In the initial characterization of such systems, Kim, *et al.* demonstrated that cancer cells within a protein 3D gel inside a microchannel had a higher viability compared to cells grown in the gel under static conditions [63]. This discrepancy may be explained by improved *in vivo*-like conditions such as increased mass transfer and/or physiological solute concentrations in the channel for which the flow and metabolite concentration characteristics can be closely modeled [160]. This is important, as even very low flow rates can dramatically influence cellular behaviors (e.g., migration) [162, 163], which can make it difficult to decouple the influence of solute gradients and flow. This is disadvantageous, for example, in the study of the effect of interstitial flow, which is typically reduced in cancer. Using a smart gel-based approach to enable decoupling, Haessler, *et al.* showed that an agarose gel could serve as a physical barrier for convective flow between channels and thereby provide a model for the study of flow-independent 3D chemotaxis [164].

The 3D microfluidic approach also makes it possible to mimic the fluid exchange between capillaries and the interstitial space, which comprises an important determinant of drug delivery and uptake in tissue [20]. Using a hydrogel-filled system, the effect of reduced interstitial flow on particle uptake with high time resolution could be studied [165]. The same principle can be used, in a simplistic manner, to mimic oxygen and nutrient uptake in transformed tissue [166].

The combination of an encapsulated compliant material with flow comes with a number of practical difficulties including how to perform cell loading, mass transfer limitations and added operational complexity. To circumvent the issue of cell loading, cancer cells may be cultured in the channel on top of a 3D MatrigelTM coating [65]. Another alternative is to produce 3D multi-cellular structures produced in a channel where the gel is replaced by a rigid pillar array [167]. Pillars and gels with higher flow resistance can also be used to stabilize more fragile gels like collagen I [162]. 3D culture in channels can also be achieved by capturing multiple cells within cell traps to form cell clusters or spheroids. Wu, *et al.* used an array of U-shaped traps to enable drug discovery screens on cancer cell clusters with a very narrow size distribution [155], which is difficult to achieve by other methods.

3.2. Technical challenges and opportunities

Introducing new technologies in biosciences is a difficult task, primarily because experimentation in this field usually relies on well-established methods. Even though a technology may seem highly promising, the hurdle of calibration and comparability to the huge database of results from standard screens can prevent the transition of the product from the lab to more wide usage. It is therefore important to involve institutions focusing on drug discovery at an early stage of the design process to ensure the development of useful tools and enable validation of novel platforms by comparison with current methods. In this section we review challenges, which must be overcome before miniaturized methods may find widespread use. Firstly, the use of microfabricated systems must be simplified [168]. Secondly, depending on the function of the system, it may need to be compatible with automated experimentation. Conversely, miniaturization has the power to improve standard analytical technologies by reducing the signal to noise ratio and by integration of several steps to reduce the time needed for an experiment but also minimize experimental errors such as sample dilution. In this section, we also discuss the possibility for improvement and innovation of analytical techniques based on the unique physical principles in miniaturized systems.

Adaptation to automatic handling systems and standard read-outs—New cell analysis methods can find wider use, provided they can be integrated into already established experimental infrastructure. This includes the adaptation of the new methods to standard well plate formats that can then be handled in automated systems for liquid exchange, cell seeding and assay analysis. For example, Meyvantsson, *et al.* elegantly integrated their passive pumping microchannels for controlled cell culture into a 96-well plate format [169]. The same group later showed that this technology could be used to perform high content chemotaxis experiments with a 50-fold increase in throughput compared to conventional assays [170]. In general, open microfabricated systems are more easily adapted for automation setups than closed systems. Closed systems still suffer from a difficult loading process, as well as the dependence on bulky pumping units. On the other hand, all types of 2D and 3D cell arrays can be easily monitored by robotic systems [140, 143, 171, 172], thereby enabling at least medium-throughput screens.

Adapting standard assay read-outs to microfabricated model systems is another means of increasing the use of these systems in cell biology and drug development research. Today, solution-based extracellular assays measuring, e.g., cell metabolites are still standard in high-throughput screening [173]. However, in the last decade image-based read-outs have been increasingly used [174] because they provide data relating to the sub-cellular level and thereby enable more detailed information about the treatment response in a given cell population. In high content screening, several signals related to cell behavior are collected to produce a matrix of information about each sample [175]. For example, measuring a number of different markers of apoptosis, e.g., nuclear fragmentation, caspase-3 activity and mitochondrial activity [176], yields a more robust output than any single parameter would. Lately, high content screening methods have been adapted to real time imaging of living cells recording effects of drugs upon cell cycle or migration [177, 178]

In contrast to animal models, as well as many standard *in vitro* systems, the cellular events in a microfabricated system can be studied by high-resolution imaging with high temporal accuracy. Even when 3D cell culture is performed within a microfabricated system, the small dimensions allow the whole sample depth to fit within the focus depth of a normal objective. There are several transparent materials that can be microfabricated, such as polystyrene [179], PDMS [180] and some hydrogels [148]. Even though PDMS is known to be relatively affordable, inert and ideal for rapid prototyping, it is a non-standard material in biological research. Therefore, rapid prototyping of thermoplastics such as polystyrene [181] and cyclic olefin polymer [182] may become very important. These methods require some additional equipment compared to soft-lithography, such as a hot press and more stable molds, but will enable the researcher to develop processes that can be transferred directly to industrialization.

Standard solution-based assays [183] can easily be adapted to the miniaturized format. The smaller volumes require fewer cells per sample. However, it is important to consider artifacts on the signal coming from surface adsorption of molecules, errors in dilutions and cell populations below a critical cell number. If such factors are taken care of by choosing appropriate material and coating, using a well-designed device and by calibrating the read-out, it is possible to assure a high signal to noise ratio. On the other hand, intracellular staining assays, such as Annexin V-PE [184] can be cell number-independent and used to measure cell response also in single cell samples. This type of Cytometry gives information of the distribution of cell response within a population. High content screening procedures require high-resolution imaging, but can be adapted to microfluidic systems if the material in the imaging area is clear and suitably thin [185].

The quantitative analysis of cells present in a 3D environment is in general challenging. Currently, typically two different approaches are utilized with satisfying results; microarray scanners to measure the integrated intensity in a 3D cell sample [150] or high-resolution confocal microscopy to determine, e.g., cell death in a high-content analysis fashion on the single cell level [62].

Microfabrication can improve conventional assays and lead to innovation of analytical techniques—There are numerous examples of how microfabrication can be used to improve existing assays, e.g., in morphology-based readouts. Using etched 3D microstructures, transformed cells could be more easily distinguished from control cells [186]. Another group showed that, as a consequence of growing cells on single-cell patterns, the signal to noise ratio is improved due to a reduced variability in intracellular organization [187]. A recent report shows how microfabrication can be used to improve the standard comet-assay, which determines the electric field-promoted travel distance of DNA fragments in an agarose gel as a measure of DNA fragmentation due to apoptosis. The new platform showed that, by microfabrication of the agarose gel, single or multiple 3D cell culture, drug exposure and DNA analysis could be combined on one substrate [188].

With a focus on the advantages of these methods and with the broadening interfacing between engineers and biologists, we could expect that many more standard methods may be simplified by microfabrication. Clearly, the miniaturization efforts will also contribute to

the development of completely new solutions for the analysis of cell behavior. A direct consequence of miniaturization is the possibility of performing single cell analysis on both adherent cells [147] and cells in suspension [189]. Single cell analyses of cells in suspension assessing individual cell mechanics, such as stretchability, have been used in a high throughput manner to differentiate between invasive and non-invasive cells [190]. By studying the cell migration through narrow constrictions in a microfabricated chip [191], the distinction between different cell types in a heterogeneous cell population is made possible [192]. Such a system could be developed towards a diagnostic tool or used as a functional read-out when assaying invasion-inhibiting drugs.

Hence, it will not be long before researchers develop methodologies for single cell drug responses using these methods (e.g., for circulating tumor cell assessments and predictions). Moreover, for adherent cells, single cell analysis on chip, with organized cell positioning in x-y-z, enables serial and time-dependent analyses of, e.g., different steps of apoptosis within a population [193]. Microfabrication also offers alternatives to microscopy-based single cell analysis by integration of chemical [194] or electrical current [195] sensor arrays placed on detection chips for fast and accurate analysis of drug response.

4. The application of microfabricated model systems for cell-based cancer drug discovery

The promise of microscale systems for improvement of cell-based assays in cancer research has led to intensive research within this field. Recent studies of novel systems usually show a relevant experimental design, in which the choice of cell type and drug or microenvironment is strongly based on the current state-of-the-art in biological *in vitro* and *in vivo* research. However, since most studies are still used to show feasibility of a method, cancer cell lines are often used for simplicity. This may be the correct choice and follow the state-of-the-art for some models, while a primary cell would have generated more relevant results in other systems. Therefore, a more thorough evaluation of many of the cited studies in this section would be needed to really show their respective predictive strengths for a certain disease types. Frequently studied cancers in these systems are breast, prostate and colon.

2D and 3D cell arrays to determine the effect of specific environmental parameters on cancer behavior and drug response

Unique aspects of cancer cell behavior and especially its dependence on the microenvironment have been discovered by the application of 2D cell arrays. In a pioneering study, the spreading area of cells on adhesive micropatterns was used to study cell growth vs. apoptosis [59]. Latter work also determined that cell-cell adhesion promoted cell division in normal cells but only when cells were sufficiently spread [196]. This result may explain some of the diverging responses to anti-mitotic-drugs in tissues with different cell densities. Interestingly, using a microwell array of cancer cell clusters, Håkanson, *et al.*, recently showed that this mechanism was highly conserved in early stages of breast cancer and was directly related to E-cadherin expression [62]. In fact, the formation of cell-cell contacts via E-cadherin also affects the secretion of vascular endothelial growth factor and interleukin-8,

indicating the importance of cell interactions in regulating the angiogenic potential of tumor cells [197]. Adhesive micropatterns have also been used to determine the importance of cell size and tissue geometry for the epithelial to mesenchymal transition [198, 199], also known as EMT, which is critical in metastasis. Furthermore, cell shape and the distribution of the adhesion environment impacted on intracellular contractility and mitotic spindle orientation [200, 201], which has also been postulated to contribute to cancer metastasis [202]. This work has now been extended into a 3D environment to reveal that cell shape is critical in controlling mitosis, regardless of the dimensionality of the microenvironment [57]. The comparison between cells cultured in square microwells *versus* 2D square patterns demonstrated that dimensionality alone also affected the progression of the cell through mitosis and spindle orientation.

3D cell arrays are favorable because of their relevance to cell behavior *in vivo*. Consequently, there has been a shift in recent years towards 3D models that simulate physiological settings. Controlling extrinsic parameters in an *in vivo* relevant environment can be used to give insight into the microenvironmental control of cell behavior. To this end, our group has proposed to use multi-well configurations of cell-derived ECMs taking advantage of the different types of ECMs produced by diverse stromal cells (e.g., normal vs. tumor-associated fibroblasts) to study matrix induced drug effects as well as cell responses to the specific ECMs in a variety of cancers [12, 13, 33, 203]. On the other hand, others have shown that microwell arrays produced in collagen I enable the study of the role of the 3D microenvironment on various cell behaviors such as branching [204], which is relevant for the control of organogenesis, angiogenesis, invasion, and metastasis. It was shown that cell branching was affected by the local geometry of the tissue and by the biochemical signaling imparted by the surrounding ECM [43]. In fact, it has been recently proposed that local changes in tissue morphogenesis are regulated by the ECM [205]. Alternatively, by producing a microwell array using inert materials, we were able to independently vary extrinsic parameters, such as ECM composition, cell-cell adhesion, stiffness as well as the dimensionality of the culture environment [47, 51, 57, 206]. In fact, we used a PEG-hydrogel microwell platform [15] to dissect the effect of the above-mentioned parameters on drug responses of multilayer cancer cell clusters [62] (Fig. 4a). In this recent study, we demonstrated that the two ECM proteins, laminin and collagen I, had discrete effects on breast cancer clusters treated with Taxol even under control of other factors such as cluster geometry and cell density. Optical sectioning of the clusters by confocal imaging revealed that Taxol response also depends on the prevalence of cell-cell versus cell-matrix interactions [62].

Controlled co-culture to separate heterogeneous cell interaction from environmental factors in cancer invasion scenarios

Homogeneous cell-cell interactions between cancer cells as well as heterogeneous interactions between cancer cells and other cell types in the microenvironment are known to be crucial for the progression of cancer and metastasis [72]. Understanding the mechanisms behind cancer cell migration (and invasion) and the role of the microenvironment is critical for the development of metastasis-inhibiting cancer therapy. The importance of homo- and heterogeneous cellular interactions in normal and cancerous cells has been studied *in vitro*

using (amongst other strategies) engineered cell-cell adherent receptor (e.g., cadherin) surface structures [51, 207–209], as well as in co-culture systems [210]. Tightly controlled co-cultures, in terms of the dimensions of colony islands and cell contacts, can be produced by microfabrication [211]. The possibility to mimic complex *in vivo* environments makes microfabrication ideally suited to study essential stages of cancer progression that rely on a complex communication with other cells, such as capillary morphogenesis and cancer cell metastasis [212]. For example, Sarkar, *et al.* developed a simple breast cancer system with cells present as single cells and colonies in an array surrounded by fibroblasts to study the role of homo- and heterotypic cell-adhesion in cell migration [213]. Chung, *et al.* used a system in which cells can migrate within a collagen I scaffold to investigate in detail the effect of cancer cells on the migration of endothelial cells, the first stage of capillary morphogenesis [214]. Rizvi, *et al.* recently showed how a Matrigel™-based microfluidic platform could be used to study the role of flow on the metastatic transformation of a human ovary carcinoma cell line [65].

Importantly, these platforms enable the separation of effects of, e.g., direct physical cell-cell contacts and paracrine signaling. This can provide valuable information for the assertive targeting of tumor-stromal interactions. It was, for example, shown that soluble signals from hepatocellular cancer cells increased the migratory activity of fibroblasts in a concentration- and time-dependent manner [215]. In another system, the microfluidic compartmentalization of a collagen I gel enabled the separation of factors, thereby unraveling two different mechanisms for the role of fibroblastic cells in the transition of breast cancer cells to migrative (invasive) cellular behaviors [216]. Both soluble factors and direct cancer cell to fibroblast cell contacts were shown to be important.

A multitude of parameters play a role in the mechanisms controlling cancer cell movement within the vascular system, including shear force. Using a device with a thin membrane separating two channels, Song, *et al.* presented a detailed study of the heterogeneous cell interactions [217]. Using an endothelial cell layer on the membrane to mimic the lining of the vessel wall, while metastatic tumor cells were perfused in the upper channel, the authors showed that the basal stimulation of the endothelium with the cytokine CXCL12 (also known as SDF-1) to mimic inflammation, significantly increased the adhesion of the cancer cells through their receptor CXCR4 [217]. In a recent report, a microfluidic device was used to study the role of CXCL12 together with the heterotypic interaction between salivary gland cancer and mesenchymal stem cells (MSCs) [218]. By 2D and 3D assays, precise cells patterning, stable chemokine gradient formation, and real-time evaluation of cell migration, some details of the heterotypic cell-cell interactions were accurately and quantitatively investigated. MSCs were observed to be recruited by neoplastic cells. Particularly, MSCs exhibited the ability to enhance the invasion of cancer cells under a chemokine CXCL12 gradient indicating the involvement of CXCL12–CXCR4 pathway and the role of MSCs in cancer progression [218].

The possibility to mimic the complex environment in tumor cell intravasation was also explored by Kamm and colleagues [219]. They developed a microfluidic-based system that recreates the tumor-vascular interface in three-dimensions allowing for high resolution, real-time imaging, and precise quantification of endothelial barrier function. In their device, the

combined effect of biochemical factors from the participating cells and cellular interactions with macrophages were studied in three dimensions. With this method, they elegantly showed that signaling with macrophages via secretion of tumor necrosis factor alpha results in endothelial barrier impairment and increased intravasation rates. Their results provide evidence that the endothelium poses a barrier to tumor cell intravasation that can be regulated by factors present in the tumor microenvironment.

In summary, these examples show how microfabricated systems can be used to recreate and control discrete and *in vivo*-relevant conditions. Using such platforms to study key cell behavior in cancer may guide the way we think about tumor-stromal interactions with the goal of developing novel therapeutic approaches.

Integrated miniaturized multi-cell type systems to study cancer drug uptake and metabolism

An interesting and exciting application of closed systems is the microscale cell culture analog (μ CCA), which consists of a physical representation of the physiologically based pharmacokinetic model [220]. The idea of these models, also termed “body-on-a-chip,” is to present an *in vitro* alternative to animal or even to patient-customized human models, which can test the uptake, distribution and metabolic digestion of a drug in different organs. For this, Sung, *et al.* combined 3D culture with controlled flow characteristics to create an *in vivo* relevant organization of different tissues for pharmacokinetic and pharmacodynamic studies. This was done in a closed flow circuit consisting of several parallel culture chambers for different cell types (cell lines derived from colon neoplasia, liver and myeloblasts) to represent tumor, liver and blood components, respectively [220]. After optimization of the residence time of an injected drug in the different compartments to mimic *in vivo* conditions, the metabolic cleavage of a pro-drug to 5-fluorouracil was successfully mimicked. A similar approach was designed to integrate the effect of intestinal absorption and hepatic metabolism of drugs against breast cancer [221] (Fig 4b). Here, the same system could be used to determine the effect of 4 different drugs on a breast carcinoma cell line in a short amount of time. Hence, these systems could offer a more efficient, reproducible and economic alternative to animal models. In contrast to standard systems, microfabrication enables the relevant cells to be brought into contact with the drug at physiologically relevant scales, concentrations and retention times. Novel developments using “body-on-a-chip” and similar systems have been recently reviewed [222, 223].

Combinatorial screening platforms for the tight regulation of environmental factors

The use of miniaturized culture systems for combinatorial studies merges the above-mentioned advantages of controlled culture parameters with the possibility to dramatically reduce material and reagent consumption. Therefore it makes sense to move ECM adhesion arrays from a multi-well plate to the microarray format [224]. Kuschel, *et al.* were amongst the first to explore the differential adhesion pattern of very few cells onto discrete matrix protein arrays [224]. Adhesion arrays can also be used for screening matrix-dependent drug responses, which have traditionally been studied using multi-well plates [225]. The proteins may also be spotted in mixtures enabling the combinatorial effect of different matrix proteins to be studied. This technology was earlier used to study of the combinatorial effect

of collagen I, -III, -IV, laminin and fibronectin on embryonic stem cell differentiation [172], while a more intricate array was recently constructed to correlate ECM ligands to metastatic behavior [171] (Fig 4c) in cancer cell lines as well as primary and metastatic tumor-derived cells. In this work, the ECM ligands and integrins specific for metastatic cell adhesion were uncovered, while determination of cell growth was used to differentiate these from ECM proteins and integrins needed for matched primary tumor cell attachment. A similar platform was previously used to determine the role of cell-ECM as well as of cell-cell interactions for the fate of mammary progenitor cells [226]. Understanding the normal tissue regulation in, for example, the mammary tissue is a good base for an increased understanding of the emergence of a particular neoplasia.

There are several examples of how closed microfabricated systems have been used to investigate the potency enhancement of combination therapies [227]. One platform, based on an integrated drug mixer, was used to determine effective combinations of vinorelbine, paclitaxel and γ -linoleic acid [228] in a breast cancer cell model. Encouragingly, the results obtained were in agreement with what has previously been observed for the same drugs in standard combinational approaches *in vitro* [229] and more importantly in patients [230].

An interesting application is the combinatorial study of matrix proteins and solutes, considering the drastic effect of cellular and ECM interactions on drug response [33, 101, 225]. The NF- κ B pathway is one of the more frequently targeted pathways in drug development. Using a diffusion-based device combined with a protein patterned substrate and studying the effects of different ECM mixtures in combination with diverse concentrations of IGF1 and TNF- α , Ying, *et al.* confirmed the interaction of soluble factors with matrix proteins in the activation the NF- κ B pathway [231]. This initial work was performed with immortalized endothelial cells but it would be expected that the same method could be applied for the study of complex cancer cell signaling.

The epithelial to mesenchymal transition, or EMT, is important in metastasis as well as in cell plasticity and therefore highly relevant for drug development. As this transition is influenced by microenvironmental factors [232], the study of this transition would profit from the controlled environment within a miniaturized system. In a feasibility experiment using alveolar epithelial type II cells, Park, *et al.* demonstrated how the role of both immobilized ECM proteins (laminin and fibronectin) and soluble factors (TGF- β 1) could be investigated in one single step [233]. The integrative analysis together with a high control of the culture environment may be particularly fruitful in the development of combination therapies targeting the cancer and its microenvironment.

Enabling the analysis of patient-derived cells by miniaturization

Miniaturized systems are particularly beneficial for the analysis of small patient cell samples. As a complementary platform to cell lines, primary cells can increase predictivity of the pre-clinical screen and ease target validation (Fig. 1) [39]. In addition, analyzing patient cells for predictive markers and dose-response curves are important tools in personalized treatment [138]. However, the culture of primary cells remains difficult since it is often hard to obtain a sufficiently large sample size [39] and a homogeneous cell population (although heterogeneity may be more representative of the human onset). In

addition, primary cells are more sensitive to tissue-culture passaging than normal cells and can dedifferentiate or acquire new genetic and/or epigenetic changes after only a short time in culture. Miniaturized systems can help in removing some of these hurdles, since the reduced sample volume makes it possible to obtain the required cell number directly from a biopsy or with only a few culturing passages. In addition, the specific-cell capture in miniaturized channels can help to purify a small cell sample from in vivo sources (e.g. blood).

Initial progress in this field is exemplified, for example, by the study of Beske, *et al.* in which sample consumption was reduced 2-fold by producing inserts for standard well plates that enabled analysis of 10 cell samples per well [234]. Moving from standard to miniaturized ECM arrays for cell adhesion assays enabled applying this platform to the characterization of cancer cells from patients [224] and, more recently, to discriminate between local primary tumor cells and cells with metastatic potential [171]. In two examples of closed microfabricated systems determining drug concentration-response curves [41] and diagnosing oncogenic kinase activity [235] in primary human leukemia cells, a much reduced number of cells were needed to produce results with signal-to-noise ratios comparable to standard assays. In fact, the cell number reduction in comparison to the conventional methods was in the most extreme case 2000-fold [235], as shown in the assay development using a model cell line. In another example, an image-based read-out facilitated single cell analysis in a microfluidic device, thereby reducing the cell numbers needed per assay even more [193]. In this device, 300 hematopoietic cells were sufficient to obtain a drug-response with a similar statistical spread to that obtained using 15,000 to 30,000 cells using conventional methods. However, while the aforementioned approaches may be powerful in cancer diagnostic and devising patient-specific treatment, reducing the experiments to a limited amount of cells may not always give a good predictivity for highly heterogenic tumors, such as renal cell carcinomas [236].

An interesting application of microfabricated systems is the analysis of circulating cancer cells (CTSs) in blood and cells from fine needle aspirates. The microfluidic platform, with its high surface area, is superior to standard methods for the capture of cancer cells present in solution [237]. This is especially important for these samples, since the concentration of CTCs may be only 1–100 per ml of blood [238]. Cells may be captured inside the chip by cell size- or cell mechanical properties-dependent and/or biochemical affinity-based methods [237–239]. This technology has been refined to create a platform that can be manufactured on a commercial scale with improved cell capture rates [240]. However, despite the promising results, no microscale system for CTC-capture is currently FDA approved [238]. Therefore, it is still important to validate the new systems, for example showing correlation to standard methods such as flow cytometry. Weigum, *et al.* developed a device for the early detection of oral cancer based on a micro-sieve for capture of the cells and subsequent analysis by immunochemistry [241]. It was shown that the levels of EGFR expression detected in the microscale device correlated well with flow cytometry results. Recent work combined the immunophenotypic isolation with post-culturing manipulations of patient cells [242] (Fig. 4d), thereby enabling further analysis of the cells after capture, e.g., determining their drug response characteristics in a single microfluidics device. These novel

tools thus open the path for multiplex analysis of patient samples, e.g., characterization of cancer cell abundance and identification of predictive markers to help in the design of personalized therapy.

5. Conclusions and Outlook

Current interdisciplinary activities in the field of miniaturization have resulted in a large number of novel *in vitro* models for the capture, analysis and drug response evaluation of cancer cells. Much effort has been expended on technological advancement of these systems, such as novel microfluidic devices with better control of the culture environment, improving cell capture and positioning techniques, as well as in the development of innovative methods for assay read-out. What has been missing for many years is a pool of experimental data obtained in such systems, which could be compared to drug response data obtained in conventional platforms and in clinical studies. Without a large pool of examples showing the advantages of the new systems in terms of predictivity, analysis of small cell samples, etc., the overall impact of microfabricated systems on modern biology continues to be mostly theoretical and thus marginal. It is encouraging to see that the increasing collaboration between engineers and biologists has resulted in an impressive amount of data on the comparison of the new systems to the conventional multi-well plate setup. However, the very important step of comparison to clinical data, proving the improved predictivity, is still largely missing.

Here we listed several examples of how these systems can be applied to cancer research. The possibility to manipulate and control the cell environment on the microscale makes these systems advantageous in comparison to standard methods. In particular, it is possible to study the role of extrinsic parameters, which are often not easy to control using other methods. Application of these platforms has increased our understanding of the interactions between cancer cells and their microenvironment.

Many of the cell systems presented in this review were developed with the motivation to find application in the clinic and pharmaceutical industry. Still, there are only a few researchers that focus on the realization of this translation into practice. The problem is especially true for closed systems, which are typically more difficult in their handling than open ones. There is an overall consent that, in order to find wide use of these systems, adaptation to automatic handling and read-out methods is needed. Identifying which are the most promising technologies that should be adapted is a demanding step, which requires bridging the specialized fields of basic biology, bioengineering, microfluidics, clinical research and engineering. A joint decision must be taken on key requirements of the device-producing industry and clinical practice.

Cancer drug development faces many challenges, however, the progression towards targeted and personalized treatment promises a bright future. Nonetheless, this direction requires more organotypic *in vitro* models and new methods for patient sample analysis. This could be a unique chance for the bioengineering community for more extensive collaborations with basic scientists and clinicians to explore the possibilities of miniaturization for cancer cell analysis. In addition to aiding in the development in environment-targeted drugs,

microfabricated systems hold a great promise in the analysis of patient cell samples to detect predictive markers and determine dose-response profiles. With successful adaptation to automated handling system, microfabricated model systems may find wide applications in developing personalized diagnosis and patient-specific therapeutic modalities.

Acknowledgments

We would like to acknowledge comments and discussions made by Dr. P. Lelkes (Temple University and Fox Chase Cancer Center) as well as effective proofreading by Mrs. E. Ragan. We are also grateful to the Swiss Competence Center for Materials Science and Technology (CCMX) and the Swiss National Science foundation (SNF) grant PA00P3_142120/1 for providing funds to MH and MC thus making this work possible. In addition, funds to EC from the Commonwealth of Pennsylvania, Fox Chase Cancer Center's Keystone Program in Personalized Kidney Cancer Therapy, The Nodal Temple-FCCC Award, The Bucks County Board of Associates (in support of pancreatic cancer research) as well as from NCI/NIH CA113451 and CA06927 were used for the completion of this document.

Abbreviations

μCCA	microscale cell culture analog
CAM-DR	cell-adhesion mediated drug resistance
CTCs	Circulating tumor cells
ECM	extracellular matrix
HGF	hepatocyte growth factor
Hh	Hedgehog
MSCs	mesenchymal stem cells
VEGF	vascular endothelial cells growth factor

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA-Cancer J Clin.* 2013; 63:11–30. [PubMed: 23335087]
2. Maziasz T, Kadambi VJ, Silverman L, Fedyk E, Alden CL. Predictive Toxicology Approaches for Small Molecule Oncology Drugs. *Toxicol Pathol.* 2010; 38:148–164. [PubMed: 20075108]
3. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? *Nat Rev Drug Discov.* 2004; 3:711–715. [PubMed: 15286737]
4. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? *Nat Rev Drug Discov.* 2007; 6:115–120. [PubMed: 17159925]
5. Teicher BA. Acute and chronic in vivo therapeutic resistance. *Biochem Pharm.* 2009; 77:1665–1673. [PubMed: 19428320]
6. Cukierman E, Bassi DE. The mesenchymal tumor microenvironment A drug-resistant niche. *Cell Adh Migr.* 2012; 6:285–296. [PubMed: 22568991]
7. Gillet JP, Varma S, Gottesman MM. The Clinical Relevance of Cancer Cell Lines. *J Natl Cancer Inst.* 2013; 105:452–458. [PubMed: 23434901]
8. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. *Nat Rev Cancer.* 2010; 10:9–22. [PubMed: 20029421]
9. Murphy E, Majeti B, Barnes L, Makale M, Weis S, Lutu-Fuga K, Wrasidlo W, Cheresh DA. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. *Proc Natl Acad Sci USA.* 2008; 105:9343–9348. [PubMed: 18607000]

10. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT. Future directions of bone-targeted therapy for metastatic breast cancer. *Nat Rev Clin Oncol*. 2010; 7:641–651. [PubMed: 20808302]
11. Paszek M, Zahir N, Johnson K, Lakins J, Rozenberg G, Gefen A, Reinhart-King C, Margulies S, Dembo M, Boettiger D, Hammer DA, Weaver VM. Tensional homeostasis and the malignant phenotype. *Cancer Cell*. 2005; 8:241–254. [PubMed: 16169468]
12. Castelló-Cros R, Khan DR, Simons J, Valianou M, Cukierman E. Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. *BMC Cancer*. 2009; 9:94. [PubMed: 19323811]
13. Goetz JG, Minguet S, Navarro-Lerida I, JLLR, Samaniego R, Calvo E, Tello M, Osteso-Ibanez T, Pellinen T, Echarrí A, Cerezo A, Klein-Szanto AJ, García R, Keely PJ, Sánchez-Mateos P, Cukierman E, Pozo MAD. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. *Cell*. 2011; 146:148–163. [PubMed: 21729786]
14. Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ. $\beta 1$ Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts. *Cancer Res*. 2008; 68:4398–4405. [PubMed: 18519702]
15. Meads M, Gatenby R, Dalton W. Environment-mediated drug resistance: a major contributor to minimal residual disease. *Nat Rev Cancer*. 2009; 9:665–674. [PubMed: 19693095]
16. Franco OE, Shaw AK, Strand DW, Hayward SW. Cancer associated fibroblasts in cancer pathogenesis. *Semin Cell Dev Biol*. 2010; 21:33–39. [PubMed: 19896548]
17. Eberle KE, Sansing HA, Szanislo P, Resto VA, Berrier AL. Carcinoma Matrix Controls Resistance to Cisplatin through Talin Regulation of NF- κ B. *PLoS ONE*. 2011; 6:e21496. [PubMed: 21720550]
18. Flach EH, Rebecca VW, Herlyn M, Smalley KS, Anderson AR. Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance. *Mol Pharm*. 2011; 8:2039–2049. [PubMed: 22067046]
19. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. *Nature*. 2012; 487:500–504. [PubMed: 22763439]
20. Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. *Biochem Pharmacol*. 2010; 80:762–770. [PubMed: 20417189]
21. Tunggal JK, Cowan DS, Shaikh H, Tannock IF. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. *Clin Cancer Res*. 1999; 5:1583–1586. [PubMed: 10389947]
22. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The Pancreas Cancer Microenvironment. *Clin Cancer Res*. 2012; 18:4266–4276. [PubMed: 22896693]
23. Kadaba R, Birke H, Wang J, Hooper S, Andl CD, Maggio FD, Soyly E, Ghallab M, Bor D, Froeling FE, Bhattacharya S, Rustgi AK, Sahai E, Chelala C, Sasieni P, Kocher HM. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. *J Pathol*. 2013; 230:107–117. [PubMed: 23359139]
24. Friedrich J, Seidel C, Ebner R, Kunz-Schughart L. Spheroid-based drug screen: considerations and practical approach. *Nat Protoc*. 2009; 4:309–324. [PubMed: 19214182]
25. Kostadinova R, Boess F, Applegate D, Suter L, Weiser T, Singer T, Naughton B, Roth A. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. *Toxicol Appl Pharmacol*. 2013; 268:1–16. [PubMed: 23352505]
26. Bhadriraju K, Chen CS. Engineering cellular microenvironments to improve cell-based drug testing. *Drug Discov Today*. 2002; 7:612–620. [PubMed: 12047872]
27. Friedrich J, Ebner R, Kunz-Schughart L. Experimental anti-tumor therapy in 3-D: Spheroids - old hat or new challenge? *Int J Radiat Biol*. 2007; 83:849–871. [PubMed: 18058370]
28. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. *Science*. 2001; 294:1708–1712. [PubMed: 11721053]
29. Trappmann B, Gautrot JE, Connelly JT, Strange DGT, Li Y, Oyen ML, Cohen Stuart MA, Boehm H, Li B, Vogel V, Spatz JP, Watt FM, Huck WTS. Extracellular-matrix tethering regulates stem-cell fate. *Nat Mater*. 2012; 11:642–649. [PubMed: 22635042]

30. Discher DE, Mooney DJ, Zandstra PW. Growth factors, matrices, and forces combine and control stem cells. *Science*. 2009; 324:1673–1677. [PubMed: 19556500]
31. Debnath J, Muthuswamy S, Brugge J. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods*. 2003; 30:256–268. [PubMed: 12798140]
32. Yamada K, Cukierman ME. Modeling tissue morphogenesis and cancer in 3D. *Cell*. 2007; 130:601–610. [PubMed: 17719539]
33. Serebriiskii I, Castelló-Cros R, Lamb A, Golemis E, Cukierman E. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. *Matrix Biol*. 2008; 27:573–585. [PubMed: 18411046]
34. Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. *BMC Cancer*. 2011; 11:245. [PubMed: 21668992]
35. Petrie RJ, Yamada KM. At the leading edge of three-dimensional cell migration. *J Cell Sci*. 2012; 125:5917–5926. [PubMed: 23378019]
36. Nelson C, Bissell M. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. *Semin Cancer Biol*. 2005; 15:342–352. [PubMed: 15963732]
37. Stein, W. CHI's Tissue Models for Therapeutics. Boston, MA, USA: 2005. Mining databases to find the genes that determine the intractability of human tumors.
38. Cree I, Glaysher S, Harvey A. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. *Curr Opin Pharmacol*. 2010; 4:375–379. [PubMed: 20570561]
39. Goldbard S. Bringing primary cells to mainstream drug development and drug testing. *Curr Opin Drug Discov Dev*. 2006; 9:110–116.
40. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. *Nat Rev Drug Discov*. 2007; 6:287–293. [PubMed: 17380152]
41. Ganser A, Roth G, van Galen JC, Hilderink J, Wammes JJG, Müller I, van Leeuwen FN, Wiesmüller KH, Brock R. Diffusion-driven device for a high-resolution dose-response profiling of combination chemotherapy. *Anal Chem*. 2009; 81:5233–5240. [PubMed: 19476343]
42. Bhatia SN, Balis UJ, Yarmush ML, Toner M. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. *FASEB Journal*. 1999; 13:1883–1900. [PubMed: 10544172]
43. Pavlovich AL, Manivannan S, Nelson CM. Adipose Stroma Induces Branching Morphogenesis of Engineered Epithelial Tubules. *Tissue Eng Part A*. 2010; 16:3719–3726. [PubMed: 20649458]
44. Xu F, Celli J, Rizvi I, Moon S, Hasan T, Demirci U. A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform. *Biotechnol J*. 2011; 6:204–212. [PubMed: 21298805]
45. Kalabis J, Wong GS, Vega ME, Natsuizaka M, Robertson ES, Herlyn M, Nakagawa H, Rustgi AK. Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. *Nat Protoc*. 2012; 7:235–246. [PubMed: 22240585]
46. Lee KY, Mooney DJ. Alginate: properties and biomedical applications. *Prog Polym Sci*. 2012; 37:106–126. [PubMed: 22125349]
47. Håkanson M, Textor M, Charnley M. Engineered 3D environments to elucidate the effect of environmental parameters on drug response in cancer. *Integr Biol*. 2011:1–8.
48. Lin L, Perets A, Har-el Y-e, Varma D, Li M, Lazarovici P, Woerdeman DL, Lelkes PI. Alimentary 'green' proteins as electrospun scaffolds for skin regenerative engineering. *J Tissue Eng Regen Med*. 2012 In press. 10.1002/term.1493
49. Lo A, Mori H, Mott J, Bissell M. Constructing Three-Dimensional Models to Study Mammary Gland Branching Morphogenesis and Functional Differentiation. *J Mammary Gland Biol Neoplasia*. 2012; 17:103–110. [PubMed: 22573197]
50. Gupta V, Bassi DE, Simons JD, Devarajan K, Al-Saleem T, Uzzo RG, Cukierman E. Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. *PLoS ONE*. 2011; 6:e21494. [PubMed: 21738681]

51. Charnley M, Kroschewski R, Textor M. The study of polarisation in single cells using model cell membranes. *Integr Biol.* 2012; 4:1059–1071.
52. Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. *Journal of visualized experiments: JoVE.* 2011
53. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. *Nat Meth.* 2007; 4:359–365.
54. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: An underestimated tool is catching up again. *J Biotechnol.* 2010; 148:3–15. [PubMed: 20097238]
55. Liu WF, Chen CS. Cellular and multicellular form and function. *Adv Drug Deliv Rev.* 2007; 59:1319–1328. [PubMed: 17884241]
56. Dusseiller M, Smith ML, Vogel V, Textor M. Microfabricated three-dimensional environments for single cell studies. *Biointerphases.* 2006; 1:1–4. [PubMed: 20408608]
57. Charnley M, Anderegg F, Holtackers R, Textor M, Meraldi P. Effect of Cell Shape and Dimensionality on Spindle Orientation and Mitotic Timing. *PLoS ONE.* 2013; 8:e66918. [PubMed: 23825020]
58. Ochsner M, Textor M, Vogel V, Smith ML. Dimensionality controls cytoskeleton assembly and metabolism of fibroblast cells in response to rigidity and shape. *PLoS ONE.* 2010; 5:e9445. [PubMed: 20351781]
59. Chen C, Mrksich M, Huang S, Whitesides G, Ingber DE. Geometric Control of Cell Life and Death. *Science.* 1997; 276:1425–1428. [PubMed: 9162012]
60. Wlodkovic D, Cooper JM. Tumors on chips: oncology meets microfluidics. *Curr Opin Chem Biol.* 2010; 14:556–557. [PubMed: 20832352]
61. Gidrol X, Fouqué B, Ghenim L, Haguët V, Picollet-D'hahan N, Schaack B. 2D and 3D cell microarrays in pharmacology. *Curr Opin Pharmacol.* 2009; 9:664–668. [PubMed: 19520607]
62. Håkanson M, Kobel S, Lutolf MP, Textor M, Cukierman E, Charnley M. Controlled breast cancer microarrays for the deconvolution of cellular multilayering and density effects upon drug responses. *PLoS ONE.* 2012; 7:e40141. [PubMed: 22792141]
63. Kim MS, Yeon JH, Park JK. A microfluidic platform for 3-dimensional cell culture and cell-based assays. *Biomed Microdevices.* 2007; 9:25–34. [PubMed: 17103048]
64. Torisawa Y, Mosadegh B, Bersano-Begey T, Steele JM, Luker KE, Luker GD, Takayama S. Microfluidic platform for chemotaxis in gradients formed by CXCL12 source-sink cells. *Integr Biol.* 2010; 2:680–686.
65. Rizvi I, Gurkan UA, Tasoglu S, Alagic N, Celli JP, Mensah LB, Mai Z, Demirci U, Hasan T. Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules. *Proc Natl Acad Sci USA.* 2013; 110:E1974–E1983. [PubMed: 23645635]
66. Montanez-Sauri SI, Sung KE, Berthier E, Beebe DJ. Enabling screening in 3D microenvironments: probing matrix and stromal effects on the morphology and proliferation of T47D breast carcinoma cells. *Integr Biol.* 2013; 5:631–640.
67. Bleicher, Bohm H, Muller K, Alanine A. Hit and lead generation: Beyond high-throughput screening. *Nat Rev Drug Discov.* 2003; 2:369–378. [PubMed: 12750740]
68. Landro JA. HTS in the new millennium: the role of pharmacology and flexibility. *J Pharmacol Toxicol Methods.* 2000; 44:273–289. [PubMed: 11274895]
69. Roberge M. Cell-based screen for antimetabolic agents and identification of analogues of rhizoxin, eleutherobin and paclitaxel in natural extracts. *Cancer Res.* 2000; 60:5052–5058. [PubMed: 11016628]
70. Balis F. Evolution of Anticancer Drug Discovery and the Role of Cell-Based Screening box. *J Natl Cancer Inst.* 2002:85.
71. Denys H, Braems G, Lambein K, Pauwels P, Hendrix A, De Boeck A, Mathieu V, Bracke M, De Wever O. The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. *Curr Pharm Des.* 2009; 15:1373–1384. [PubMed: 19355975]
72. Joyce J, Pollard J. Microenvironmental regulation of metastasis. *Nat Rev Cancer.* 2009; 9:239–252. [PubMed: 19279573]

73. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. *Differentiation*. 2002; 70:537–546. [PubMed: 12492495]
74. Sonnenschein C, Soto AM. The Death of the Cancer Cell. *Cancer Res*. 2011; 71:4334–4337. [PubMed: 21507929]
75. Hofmeister V, Schrama D, Becker JC. Anti-cancer therapies targeting the tumor stroma. *Cancer Immunol Immunother*. 2008; 57:1–17. [PubMed: 17661033]
76. Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A, Giese NA, Esposito I, Friess H, Kleeff J. The Activated Stroma Index Is a Novel and Independent Prognostic Marker in Pancreatic Ductal Adenocarcinoma. *Clin Gastroenterol Hepatol*. 2008; 6:1155–1161. [PubMed: 18639493]
77. Paget S. The distribution of secondary growths in cancer of the breast. *The Lancet*. 1889; 133:571–573.
78. Langhans T. Pulsirende cavernöse Geschwulst der Miltz mit metastatischen Knoten in der Leber. *Virchows Archiv*. 1879; 75:273–291.
79. Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: The force journey of a tumor cell. *Cancer Metast Rev*. 2009; 28:113–127.
80. Beacham DA, Cukierman E. Stromagenesis: The changing face of fibroblastic microenvironments during tumor progression. *Semin Cancer Biol*. 2005; 15:329–341. [PubMed: 15970443]
81. Cook LM, Hurst DR, Welch DR. Metastasis suppressors and the tumor microenvironment. *Semin Cancer Biol*. 2011; 21:113–122. [PubMed: 21168504]
82. Witz IP, Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. *Cancer Lett*. 2006; 242:1–10. [PubMed: 16413116]
83. Tarin D. Clinical and Biological Implications of the Tumor Microenvironment. *Cancer microenviron*. 2012; 5:95–112. [PubMed: 22782446]
84. Rønnov-Jessen L, Bissell M. Breast cancer by proxy: can the microenvironment be both the cause and consequence? *Trends Mol Med*. 2008; 15:5–13. [PubMed: 19091631]
85. Kunz-Schughart LA, Knuechel R. Tumor associated fibroblasts (Part II): functional impact on tumor tissue. *Histol Histopathol*. 2002; 2:623–637. [PubMed: 11962762]
86. Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, Friedl A, Keely PJ. Aligned Collagen Is a Prognostic Signature for Survival in Human Breast Carcinoma. *Am J Pathol*. 2011; 178:1221–1232. [PubMed: 21356373]
87. Amatangelo MD, Bassi DE, Klein-Szanto AJ, Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. *Am J Pathol*. 2005; 167:475–488. [PubMed: 16049333]
88. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SFT, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM. Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling. *Cell*. 2009; 139:891–906. [PubMed: 19931152]
89. Bissell M, LaBarge M. Context, tissue plasticity, and cancer Are tumor stem cells also regulated by the microenvironment? *Cancer Cell*. 2005; 7:17–23. [PubMed: 15652746]
90. Polanska UM, Orimo A. Carcinoma-associated fibroblasts: Non-neoplastic tumour-promoting mesenchymal cells. *J Cell Physiol*. 2013; 228:1651–1657. [PubMed: 23460038]
91. Castelló-Cros R, Cukierman E. Stromagenesis during tumorigenesis: characterization of tumor-associated fibroblasts and stroma-derived 3D Matrices. *Methods mol biol*. 2009; 522:275–305. [PubMed: 19247611]
92. Mehner C, Radisky DC. Triggering the landslide: The tumor-promotional effects of myofibroblasts. *Exp cell res*. 2013; 319:1657–1662.
93. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. *J Cell Biol*. 2012; 196:395–406. [PubMed: 22351925]
94. Oskarsson T, Massague J. Extracellular matrix players in metastatic niches. *EMBO J*. 2012; 31:254–256. [PubMed: 22179697]
95. Otranto M, Sarrazy V, Bonté F, Hinz B, Gabbiani G, Desmouliere A. The role of the myofibroblast in tumor stroma remodeling. *Cell Adh Migr*. 2012; 6:203–219. [PubMed: 22568985]

96. Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. *Biochem J.* 2012; 441:541–552. [PubMed: 22187935]
97. Strell C, Rundqvist H, Östman A. Fibroblasts—a key host cell type in tumor initiation, progression, and metastasis. *Ups J Med Sci.* 2012; 117:187–195. [PubMed: 22509805]
98. Wittekind C, Neid M. Cancer invasion and metastasis. *Oncology.* 2005; 69:14–16. [PubMed: 16210871]
99. Jodele S, Blavier L, Yoon JM, DeClerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. *Cancer Metastasis Rev.* 2006; 25:35–43. [PubMed: 16680570]
100. Ronnov-Jessen L, Petersen O, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction. *Physiol Rev.* 1996; 76:69–125. [PubMed: 8592733]
101. Paraiso KHT, Smalley KSM. Fibroblast-mediated drug resistance in cancer. *Biochem Pharmacol.* 2013; 85:1033–1041. [PubMed: 23376122]
102. Minchinton A, Tannock IF. Drug penetration in solid tumors. *Nat Rev Cancer.* 2006; 6:583–592. [PubMed: 16862189]
103. St Croix B, Sheehan C, Rak JW, Flørenes VA, Slingerland JM, Kerbel RS. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). *J Cell Biol.* 1998; 142:557–571. [PubMed: 9679152]
104. Hazlehurst LA, Landowski TH, Dalton WS. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. *Oncogene.* 2003; 22:7396–7402. [PubMed: 14576847]
105. Aoudjit F, Vuori K. Integrin Signaling in Cancer Cell Survival and Chemoresistance. *Chemother Res Pract.* 2012; 2012:16.
106. Quiros RM, Valianou M, Kwon Y, Brown KM, Godwin AK, Cukierman E. Ovarian normal and tumor-associated fibroblasts retain *in vivo* stromal characteristics in a 3-D matrix-dependent manner. *Gynecol Oncol.* 2008; 110:99–109. [PubMed: 18448156]
107. Sherman-Baust C, Weeraratna A, Rangel L, Pizer E, Cho K, Schwartz D, Schock T, Morin P. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. *Cancer Cell.* 2003; 3:377–386. [PubMed: 12726863]
108. Lito P, Pratilas Christine A, Joseph Eric W, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong Wai L, Callahan Margaret K, Merghoub T, Wolchok Jedd D, de Stanchina E, Chandraratna S, Poulikakos Poulikos I, Fagin James A, Rosen N. Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. *Cancer Cell.* 2012; 22:668–682. [PubMed: 23153539]
109. Fischbach C. Complex engineering models to recapitulate tumor-stroma interactions and their effect on drug delivery. *Adv Drug Deliv Rev.* 2014 editor to update this citation accordingly (thanks).
110. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. *Adv Drug Deliv Rev.* 2011; 63:136–151. [PubMed: 20441782]
111. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. *Adv Drug Deliv Rev.* 2012; 64(Supplement):206–212.
112. Polyak D, Eldar-Boock A, Baabur-Cohen H, Satchi-Fainaro R. Polymer conjugates for focal and targeted delivery of drugs. *Polym Adv Technol.* 2013; 24:777–790.
113. Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. *Eur J Pharm Sci.* 2013; 48:416–427. [PubMed: 23262059]
114. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. *Nature biotechnol.* 2005; 23:1147–1157. [PubMed: 16151408]
115. Boder, ET.; Jiang, W. Engineering Antibodies for Cancer Therapy. In: Prausnitz, JM., editor. *Annu Rev Chem Biomol Eng.* Vol. 2. 2011. p. 53-75.

116. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. *Adv Drug Deliv Rev.* 2008; 60:1615–1626. [PubMed: 18840489]
117. Morgan JP, Delnero PF, Zheng Y, Verbridge SS, Chen J, Craven M, Choi NW, Diaz-Santana A, Kermani P, Hempstead B, Lopez JA, Corso TN, Fischbach C, Stroock AD. Formation of microvascular networks in vitro. *Nature protoc.* 2013; 8:1820–1836. [PubMed: 23989676]
118. Verbridge SS, Chakrabarti A, Delnero P, Kwee B, Varner JD, Stroock AD, Fischbach C. Physicochemical regulation of endothelial sprouting in a 3D microfluidic angiogenesis model. *J Biomed Mater Res A Part A.* 2013; 101:2948–2956.
119. Heller E, Hurchla MA, Xiang J, Su X, Chen S, Schneider J, Joeng KS, Vidal M, Goldberg L, Deng H, Hornick MC, Prior JL, Piwnica-Worms D, Long F, Cagan R, Weilbaecher KN. Hedgehog Signaling Inhibition Blocks Growth of Resistant Tumors through Effects on Tumor Microenvironment. *Cancer Res.* 2012; 72:897–907. [PubMed: 22186138]
120. Hehlhans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. *BBA; Rev Cancer.* 2007; 1775:163–180.
121. Hazlehurst LA, Argilagos RF, Dalton WS. $\beta 1$ integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. *Br J Haematol.* 2007; 136:269–275. [PubMed: 17233818]
122. Lwin T, Hazlehurst L, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao JG. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. *Blood.* 2007; 110:1631–1638. [PubMed: 17502456]
123. Yao E, Zhang H, Chen Y, Lee B, Chew K. Increased $\beta 1$ Integrin Is Associated with Decreased Survival in Invasive Breast Cancer. *Cancer Res.* 2007
124. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bisell MJ. $\beta 1$ Integrin Inhibitory Antibody Induces Apoptosis of Breast Cancer Cells, Inhibits Growth, and Distinguishes Malignant from Normal Phenotype in Three Dimensional Cultures and In vivo. *Cancer Res.* 2006; 66:1526–1535. [PubMed: 16452209]
125. Wang H, Fu WL, Im JH, Zhou ZY, Santoro SA, Iyer V, DiPersio CM, Yu QC, Quaranta V, Al-Medhi A, Muschel RJ. Tumor cell $\alpha 3\beta 1$ integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. *J cell biol.* 2004; 164:935–941. [PubMed: 15024036]
126. Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, Williams P, Mundy G, Yoneda T. Anti-alpha 4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. *Blood.* 2004; 104:2149–2154. [PubMed: 15138161]
127. Manegold C, Vansteenkiste J, Cardenal F, Schuette W, Woll PJ, Ulsperger E, Kerber A, Eckmayr J, von Pawel J. Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. *Invest New Drugs.* 2013; 31:175–182. [PubMed: 22752690]
128. Patel S, Jenkins J, Papadopolous N, Burgess M, Plager C, Gutterman J, Benjamin R. Pilot study of Vitaxin - An angiogenesis inhibitor - In patients with advanced leiomyosarcomas. *Cancer.* 2001; 92:1347–1348. [PubMed: 11571751]
129. Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, Marty M, Faivre S. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. *Invest New Drugs.* 2008; 26:35–43. [PubMed: 17876527]
130. Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M, Hammershaimb L, Kirkwood JM. G. Etaracizumab Melanoma Study. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or – dacarbazine in patients with stage IV metastatic melanoma. *Cancer.* 2010; 116:1526–1534. [PubMed: 20108344]
131. Moschos SJ, Sander CA, Wang W, Reppert SL, Drogowski LM, Jukic DM, Rao UN, Athanassiou C, Buzoianu M, Mandic M, Richman L, McKinney L, Leininger J, Tice DA, Hammershaimb L, Kirkwood JM. Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. *J Immunother.* 2010; 33:316–325. [PubMed: 20445352]
132. Marling J, Pisoni I, Neri D. Tumor vascular targeting. *Drugs Future.* 2006; 31:901–913.

133. Hood J, Bednarski M, Frausto R, Guccione S, Reisfeld R, Xiang R, Cheresch DA. Tumor regression by targeted gene delivery to neovasculature. *Science*. 2002; 296:2404–2407. [PubMed: 12089446]
134. Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A, Giese NA, Esposito I, Friess H, Kleeff J. The Activated Stroma Index Is a Novel and Independent Prognostic Marker in Pancreatic Ductal Adenocarcinoma. *Clin Gastroenterol Hepatol*. 2008; 6:1155–1161. [PubMed: 18639493]
135. Jia Z, Wang Y, Sawyers A, Yao H, Rahmatpanah F, Xia XQ, Xu Q, Pio R, Turan T, Koziol JA, Goodison S, Carpenter P, Wang-Rodriguez J, Simoneau A, Meyskens F, Sutton M, Lernhardt W, Beach T, Monforte J, McClelland M, Mercola D. Diagnosis of Prostate Cancer Using Differentially Expressed Genes in Stroma. *Cancer Res*. 2011; 71:2476–2487. [PubMed: 21459804]
136. Niu H, Jiang H, Cheng B, Li X, Dong Q, Shao L, Liu S, Wang X. Stromal proteome expression profile and muscle-invasive bladder cancer research. *Cancer Cell Int*. 2012; 12:39. [PubMed: 22920603]
137. Harbeck N, Salem M, Nitz U, Gluz O, Liedtke C. Personalized treatment of early-stage breast cancer: Present concepts and future directions. *Cancer Treat Rev*. 2010; 36:584–594. [PubMed: 20554119]
138. BM. Novel pathways and biomarkers unraveled by complex biological models. *Adv Drug Deliv Rev*. 2014editor to update this citation accordingly (thanks)
139. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. *Mol Cancer Ther*. 2011; 10:1311–1316. [PubMed: 21673092]
140. Underhill GH, Galie P, Chen CS, Bhatia SN. Bioengineering methods for analysis of cells in vitro. *Annu Rev Cell Dev Biol*. 2012; 28:385–410. [PubMed: 23057744]
141. Faia-Torres, A.; Goren, T.; Textor, M.; Pla-Roca, M. *Comprehensive Biomaterials*. Elsevier; 2011. Patterned Biointerfaces.
142. Falconnet D, Csucs G, Grandin HM, Textor M. Surface engineering approaches to micropattern surfaces for cell-based assays. *Biomaterials*. 2006; 27:3044–3063. [PubMed: 16458351]
143. Azioune A, Storch M, Bornens M, Théry M, Piel M. Simple and rapid process for single cell micro-patterning. *Lab Chip*. 2009; 9:1640–1642. [PubMed: 19458875]
144. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW, Martin GR. Basement membrane complexes with biological activity. *Biochemistry*. 1986; 25:312–318. [PubMed: 2937447]
145. Sodunke TR, Turner KK, Caldwell SA, McBride KW, Reginato MJ, Noh HM. Micropatterns of Matrigel for three-dimensional epithelial cultures. *Biomaterials*. 2007; 28:4006–4016. [PubMed: 17574663]
146. Nelson C, Inman J, Bissell M. Three-dimensional lithographically defined organotypic tissue arrays for for quantitative analysis of morphogenesis and neoplastic progression. *Nat Protoc*. 2008; 3:674–678. [PubMed: 18388950]
147. Ochsner M, Dusseiller MR, Grandin HM, Luna-Morris S, Textor M, Vogel V, Smith ML. Micro-well arrays for 3D shape control and high resolution analysis of single cells. *Lab Chip*. 2007; 7:1074–1077. [PubMed: 17653351]
148. Lutolf M, Doyonnas R, Havenstrite K, Koleckar K, Blau HM. Perturbation of single hematopoietic stem cell fates in artificial niches. *Integr Biol*. 2009; 1:59–69.
149. Zhao R, Boudou T, Wang WG, Chen CS, Reich DH. Decoupling Cell and Matrix Mechanics in Engineered Microtissues Using Magnetically Actuated Microcantilevers. *Adv Mater*. 2013; 25:1699–1705. [PubMed: 23355085]
150. Lee M, Kumar R, Sukumaran S, Hogg M, Clark D, Dordick J. Three-dimensional cellular microarray for high-throughput toxicology assays. *Proc Natl Acad Sci USA*. 2008; 105:59. [PubMed: 18160535]

151. Pla-Roca M, Leulmi RF, Djambazian H, Sundararajan S, Juncker D. Addressable nanowell arrays formed using reversibly sealable hybrid elastomer-metal stencils. *Anal Chem.* 2010; 82:3848–3855. [PubMed: 20377190]
152. Bailey SN, Sabatini DM, Stockwell RN. Microarrays of small molecules embedded in biodegradable polymers for use in mammalian cell-based screens. *Proc Natl Acad Sci USA.* 2004; 101:16144–16149. [PubMed: 15534212]
153. Young EWK, Beebe DJ. Fundamentals of microfluidic cell culture in controlled microenvironments. *Chem Soc Rev.* 2010; 39:1036. [PubMed: 20179823]
154. Pihl J, Sinclair J, Sahlin E, Karlsson M, Petterson F, Olofsson J, Orwar O. Microfluidic gradient-generating device for pharmacological profiling. *Anal Chem.* 2005; 77:3897–3903. [PubMed: 15987089]
155. Wu LY, Di Carlo D, Lee LP. Microfluidic self-assembly of tumor spheroids for anticancer drug discovery. *Biomed Microdevices.* 2008; 10:197–202. [PubMed: 17965938]
156. Takayama S, Ostuni E, LeDuc P, Naruse K, Ingber DE, Whitesides GM. Subcellular positioning of small molecules. *Nature.* 2001; 411:1016. [PubMed: 11429594]
157. Gómez-Sjöberg R, Leyrat AA, Pirone DM, Chen CS, Quake SR. Versatile, fully automated, microfluidic cell culture system. *Anal Chem.* 2007; 79:8557–8563. [PubMed: 17953452]
158. Meyer AS, Hughes-Alford SK, Kay JE, Castillo A, Wells A, Gertler FB, Lauffenburger DA. 2D protrusion but not motility predicts growth factor-induced cancer cell migration in 3D collagen. *J cell biol.* 2012; 197:721–729. [PubMed: 22665521]
159. Doyle AD, Wang FW, Matsumoto K, Yamada KM. One-dimensional topography underlies three-dimensional fibrillar cell migration. *J cell biol.* 2009; 184:481–490. [PubMed: 19221195]
160. Choi NW, Cabodi M, Held B, Gleghorn JP, Bonassar LJ, Stroock AD. Microfluidic scaffolds for tissue engineering. *Nat Mater.* 2007; 6:908–915. [PubMed: 17906630]
161. Lii J, Hsu WJ, Parsa H, Das A, Rouse R, Sia SK. Real-time microfluidic system for studying mammalian cells in 3D microenvironments. *Anal Chem.* 2008; 80:3640–3647. [PubMed: 18393530]
162. Haessler U, Teo JCM, Foretay D, Renaud P, Swartz MA. Migration dynamics of breast cancer cells in a tunable 3D interstitial flow chamber. *Integr Biol.* 2012; 4:401–409.
163. Irimia D, Charras G, Agrawal N, Mitchison T, Toner M. Polar stimulation and constrained cell migration in microfluidic channels. *Lab Chip.* 2007; 7:1783–1790. [PubMed: 18030401]
164. Haessler U, Kalinin Y, Swartz MA, Wu M. An agarose-based microfluidic platform with a gradient buffer for 3D chemotaxis studies. *Biomed Microdevices.* 2009; 11:827–835. [PubMed: 19343497]
165. Ng CP, Pun SH. A perfusable 3D cell-matrix tissue culture chamber for in situ evaluation of nanoparticle vehicle penetration and transport. *Biotechnol and Bioeng.* 2008; 99:1490–1501.
166. Walsh CL, Babin BM, Kasinskas RW, Foster JA, McGarry MJ, Forbes NS. A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics. *Lab Chip.* 2009; 9:545–554. [PubMed: 19190790]
167. Ong SM, Zhang C, Toh YC, Kim SH, Foo HL, Tan CH, van Noort D, Park S, Yu H. A gel-free 3D microfluidic cell culture system. *Biomaterials.* 2008; 29:3237–3244. [PubMed: 18455231]
168. Meyvantsson I, Beebe DJ. Cell culture models in microfluidic systems. *Annu Rev Anal Chem (Palo Alto Calif).* 2008; 1:423–449. [PubMed: 20636085]
169. Meyvantsson I, Warrick J, Hayes S, Skoien A, Beebe D. Automated cell culture in high density tubeless microfluidic device arrays. *Lab Chip.* 2008; 8:717–724. [PubMed: 18432341]
170. Berthier E, Surfus J, Verbsky J, Huttenlocher A, Beebe DJ. A high-content chemotaxis assay for patient diagnosis. *Integr Biol.* 2010; 2:630–638.
171. Reticker-Flynn NE, Malta DFB, Winslow MM, Lamar JM, Xu MJ, Underhill GH, Hynes RO, Jacks TE, Bhatia SN. A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis. *Nat Commun.* 2012; 3:1122. [PubMed: 23047680]
172. Flaim CJ, Chien S, Bhatia SN. An extracellular matrix microarray for probing cellular differentiation. *Nat Meth.* 2005; 2:119–125.

173. Niles A, Moravec RA, Riss TL. Update on in vitro cytotoxicity assays for drug development. *Expert Opin Drug Discov.* 2008; 3:655–669. [PubMed: 23506147]
174. Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC, Burlingame AL, Trautman JK, Shokat KM, Adams CL. An Unbiased Cell Morphology–Based Screen for New, Biologically Active Small Molecules. *PLoS Biol.* 2005; 3
175. Lang P, Yeow K, Nichols A, Scheer A. Cellular imaging in drug discovery. *Nat Rev Drug Discov.* 2006; 5:343–356. [PubMed: 16582878]
176. Lövborg H, Nygren P, Larsson R. Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. *Mol Cancer Ther.* 2004; 3:521–526. [PubMed: 15141009]
177. Errington, RJ.; Chappell, SC.; Khan, IA.; Marquez, N.; Wiltshire, M.; Griesdoorn, VD.; Smith, PJ. Time-lapse microscopy approaches to track cell cycle and lineage progression at the single-cell level. In: Paul Robinson, J., et al., editors. *Current protocols in cytometry/editorial board.* Vol. Chapter 12. 2013. p. 14
178. van Roosmalen W, Le Devedec SE, Zovko S, de Bont H, van de Water B. Functional screening with a live cell imaging-based random cell migration assay. *Methods in molecular biology* (Clifton, NJ). 2011; 769:435–448.
179. Dusseiller M, Schlaepfer D, Koch M, Kroschewski R, Textor M. An inverted microcontact printing method on topographically structured polystyrene chips for arrayed micro-3-D culturing of single cells. *Biomaterials.* 2005; 26:5917–5925. [PubMed: 15949557]
180. Younan X, Whitesides G. Soft lithography. *Annu Rev Marer Sci.* 1998:33.
181. Young EWK, Berthier E, Guckenberger DJ, Sackmann E, Lamers C, Mayvantsson I, Huttenlocher A, Beebe DJ. Rapid prototyping of arrayed microfluidic systems in polystyrene for cell-based assays. *Anal Chem.* 2011; 83:1408–1417. [PubMed: 21261280]
182. Jeon JS, Chung S, Kamm RD, Charest JL. Hot embossing for fabrication of a microfluidic 3D cell culture platform. *Biomed Microdevices.* 2011; 13:325–333. [PubMed: 21113663]
183. Wang Z, Kim MC, Marquez M, Thorsen T. High-density microfluidic arrays for cell cytotoxicity analysis. *Lab Chip.* 2007; 7:740. [PubMed: 17538716]
184. Reif RD, Martinez MM, Wang K, Pappas D. Simultaneous cell capture and induction of apoptosis using anti-CD95 affinity microdevice. *Anal Bioanal Chem.* 2009; 395:787–795. [PubMed: 19685232]
185. Ye N, Qin J, Shi W, Liu X, Lin B. Cell-based high content screening using an integrated microfluidic device. *Lab Chip.* 2007; 7:1696–1704. [PubMed: 18030389]
186. Strobl JS, Nikkhah M, Agah M. Actions of the anti-cancer drug suberoylanilide hydroxamic acid (SAHA) on human breast cancer cytoarchitecture in silicon microstructures. *Biomaterials.* 2010; 31:7043–7050. [PubMed: 20579727]
187. Schauer K, Duong T, Bleakley K, Bardin S, Bornens M, Goud B. Probabilistic density maps to study global endomembrane organization. *Nat Meth.* 2010; 7:560–566.
188. Mercey E, Obeid P, Glaise D, Calvo-Munoz ML, Guguen-Guillouzo C, Fouque B. The application of 3D micropatterning of agarose substrate for cell culture and in situ comet assays. *Biomaterials.* 2010; 31:3156–3165. [PubMed: 20149429]
189. Lindstrom S, Andersson-Svahn H. Overview of single-cell analyses: microdevices and applications. *Lab Chip.* 2010; 10:3363–3372. [PubMed: 20967379]
190. Lautenschläger F, Paschke S, Schinkinger S, Bruel A, Beil M, Guck J. The regulatory role of cell mechanics for migration of differentiating myeloid cells. *Proc Natl Acad Sci USA.* 2009; 106:15696–15701. [PubMed: 19717452]
191. Rolli CG, Seufferlein T, Kemkemer R, Spatz J. Impact of Tumor Cell Cytoskeleton Organization on Invasiveness and Migration: A Microchannel-Based Approach. *PLoS ONE.* 2010; 5:e8726. [PubMed: 20090950]
192. Irimia D, Toner M. Spontaneous migration of cancer cells under conditions of mechanical confinement. *Integr Biol.* 2009; 1:506–512.
193. Wlodkovic D, Faley S, Zagnoni M, Wikswo JP, Cooper JM. Microfluidic single-cell array cytometry for the analysis of tumor apoptosis. *Anal Chem.* 2009; 81:5517–5523. [PubMed: 19514700]

194. Generelli S, Jacquemart R, de Rooij NF, Jolicoeur M, Koudelka-Hep M, Guenat OT. Potentiometric platform for the quantification of cellular potassium efflux. *Lab Chip*. 2008; 8:1210–1215. [PubMed: 18584100]
195. Wolf P, Rothermel A, Beck-Sickinger AG, Robitzki AA. Microelectrode chip based real time monitoring of vital MCF-7 mamma carcinoma cells by impedance spectroscopy. *Biosens Bioelectronics*. 2008; 24:253–259.
196. Nelson C, Chen C. Cell-cell signaling by direct contact increases cell proliferation via a PI3K-dependent signal. *FEBS Letters*. 2002; 514:238–242. [PubMed: 11943158]
197. Tan C, Seo B, Brooks D, Chandler E, Craighead H, Fischbach C. Parylene peel-off arrays to probe the role of cell–cell interactions in tumour angiogenesis. *Integr Biol*. 2009; 1:587–594.
198. Nelson CM, Khauv D, Bissell MJ, Radisky DC. Change in cell shape is required for matrix metalloproteinase-induced epithelial-mesenchymal transition of mammary epithelial cells. *J Cell Biochem*. 2008; 105:25–33. [PubMed: 18506791]
199. Gomez EW, Chen QK, Gjorevski N, Nelson CM. Tissue Geometry Patterns Epithelial-Mesenchymal Transition Via Intercellular Mechanotransduction. *J of Cell Biochem*. 2010; 110:44–51. [PubMed: 20336666]
200. Théry M, Racine V, Pepin A, Piel M, Chen Y, Sibarta JB, Bornens M. The extracellular matrix guides the orientation of the cell division axis. *Nat Cell Biol*. 2005; 7:947–953. [PubMed: 16179950]
201. Tseng Q, Wang I, Duchemin-Pelletier E, Azioune A, Carpi N, Gao J, Filhol O, Piel M, Thery M, Balland M. A new micropatterning method of soft substrates reveals that different tumorigenic signals can promote or reduce cell contraction levels. *Lab Chip*. 2011; 11:2231–2240. [PubMed: 21523273]
202. Vasiliev JM, Omelchenko T, Gelfand IM, Feder HH, Bonder EM. Rho overexpression leads to mitosis-associated detachment of cells from epithelial sheets: A link to the mechanism of cancer dissemination. *Proc Natl Acad Sci USA*. 2004; 101:12526–12530. [PubMed: 15304643]
203. Kwon Y, Cukierman E, Godwin AK. Differential Expression of Adhesive Molecules and Proteases Define Mechanisms of Ovarian Tumor Cell Matrix Penetration/Invasion. *PLoS ONE*. 2011; 6:e18872. [PubMed: 21526198]
204. Nelson CM, Vanduijn MM, Inman JL, Fletcher DA, Bissell MJ. Tissue Geometry Determines Sites of Mammary Branching Morphogenesis in Organotypic Cultures. *Science*. 2006; 314:298–300. [PubMed: 17038622]
205. Daley WP, Yamada KM. ECM-modulated cellular dynamics as a driving force for tissue morphogenesis. *Curr Opin Genet Dev*. 2013; 23:408–414. [PubMed: 23849799]
206. Charnley M, Textor M, Khademhosseini A, Lutolf M. Integration column: microwell arrays for mammalian cell culture. *Integr Biol*. 2009; 1:625–634.
207. den Elzen N, BATTERY CV, Maddugoda MP, Ren G, Yap AS. Cadherin adhesion receptors orient the mitotic spindle during symmetric cell division in mammalian epithelia. *Mol Biol Cell*. 2009; 20:3740–3750. [PubMed: 19553471]
208. Tsai J, Kam LC. Lateral Mobility of E-Cadherin Enhances Rac1 Response in Epithelial Cells. *Cell Mol Bioeng*. 2010; 3:84–90. [PubMed: 20368760]
209. Andreasson-Ochsner M, Romano G, Hakanson M, Smith ML, Leckband DE, Textor M, Reimhult E. Single cell 3-D platform to study ligand mobility in cell-cell contact. *Lab Chip*. 2011; 11:2876–2883. [PubMed: 21773619]
210. Bourhis, X Dong-Le; Berthois, Y.; Millot, G.; Degeorges, A.; Sylvi, M.; Martin, P-M.; Calvo, F. Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. *Int J Cancer*. 1997; 71:42–48. [PubMed: 9096664]
211. Albrecht DR, Underhill GH, Wassermann TB, Sah RL, Bhatia SN. Probing the role of multicellular organization in three-dimensional microenvironments. *Nat Meth*. 2006; 3:369–375.
212. Huang Y, Agrawal B, Sun D, Kuo JS, Williams JC. Microfluidics-based devices: New tools for studying cancer and cancer stem cell migration. *Biomicrofluidics*. 2011; 5:013412.

213. Sarkar S, Bustard BL, Welter JF, Baskaran H. Combined experimental and mathematical approach for development of microfabrication-based cancer migration assay. *Ann Biomed Eng.* 2011; 39:2346–2359. [PubMed: 21701934]
214. Chung S, Sudo R, Mack PJ, Wan CR, Vickerman V, Kamm RD. Cell migration into scaffolds under co-culture conditions in a microfluidic platform. *Lab Chip.* 2009; 9:269–275. [PubMed: 19107284]
215. Liu W, Li L, Wang X, Ren L, Wang X, Wang J, Tu Q, Huang X, Wang J. An integrated microfluidic system for studying cell-microenvironmental interactions versatily and dynamically. *Lab Chip.* 2010; 10:1717–1724. [PubMed: 20422110]
216. Sung KE, Yang N, Pehlke C, Keely PJ, Eliceiri KW, Friedl A, Beebe DJ. Transition to invasion in breast cancer: a microfluidic in vitro model enables examination of spatial and temporal effects. *Integr Biol.* 2011; 3:439–450.
217. Song JW, Cavnar SP, Walker AC, Luker KE, Gupta M, Tung YC, Luker GD, Takayama S. Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells. *PLoS ONE.* 2009; 4:e5756. [PubMed: 19484126]
218. Ma H, Zhang M, Qin J. Probing the role of mesenchymal stem cells in salivary gland cancer on biomimetic microdevices. *Integr Biol.* 2012; 4:522–530.
219. Zervantonakis IK, Hughes-Alford SK, Charest JL, Condeelis JS, Gertler FB, Kamm RD. Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. *Proc Natl Acad Sci USA.* 2012; 109:13515–13520. [PubMed: 22869695]
220. Sung JH, Shuler ML. A micro cell culture analog (mu CCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. *Lab Chip.* 2009; 9:1385–1394. [PubMed: 19417905]
221. Imura Y, Sato K, Yoshimura E. Micro total bioassay system for ingested substances: assessment of intestinal absorption, hepatic metabolism and bioactivity. *Anal Chem.* 2010; 82:9983–9988. [PubMed: 21090751]
222. Sung JH, Esch MB, Prot JM, Long CJ, Smith A, Hickman JJ, Shuler ML. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. *Lab Chip.* 2013; 13:1201–1212. [PubMed: 23388858]
223. Sung JH, Shuler ML. Microtechnology for mimicking in vivo tissue environment. *Ann Biomed Eng.* 2012; 40:1289–1300. [PubMed: 22215276]
224. Kuschel C, Steuer H, Maurer AN, Kanzok B, Stoop R, Angres B. Cell adhesion profiling using extracellular matrix protein microarrays. *BioTechniques.* 2006; 40:523–531. [PubMed: 16629399]
225. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. *Oncogene.* 2001; 20:4995–5004. [PubMed: 11526484]
226. Labarge MA, Nelson CM, Villadsen R, Fridriksdottir A, Ruth JR, Stampfer MR, Petersen OW, Bissell MJ. Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments. *Integr Biol.* 2009; 1:70.
227. Dancy JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. *Nat Rev Drug Discov.* 2006; 5:649–659. [PubMed: 16883303]
228. Liu MC, Tai YC. A 3-D microfluidic combinatorial cell array. *Biomed Microdevices.* 2011; 13:191–201. [PubMed: 21063783]
229. Menendez J, Roper S, del Mar Barbacid M, Montero S, Solanas M, Escrich E, Cortes-Funes H, Colomer R. Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. *Breast Cancer Res Treat.* 2002; 72:203–219. [PubMed: 12058962]
230. Chang A, Garrow G. Pilot-study of vinorelbine (navelbine) and paclitaxel (taxol) in patients with refractory breast-cancer and lung-cancer. *Semin Oncol.* 1995; 22:66–71. [PubMed: 7740336]
231. Yin Z, Tao SC, Cheong R, Zhu H, Levchenko A. An integrated micro-electro-fluidic and protein arraying system for parallel analysis of cell responses to controlled microenvironments. *Integr Biol.* 2010; 2:416–423.
232. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA. Alveolar epithelial cell mesenchymal transition develops in vivo during

- pulmonary fibrosis and is regulated by the extracellular matrix. *Proc Natl Acad Sci USA*. 2006; 103:13180–13185. [PubMed: 16924102]
233. Park ES, Brown AC, Difeo MA, Barker TH, Lu H. Continuously perfused, non-cross-contaminating microfluidic chamber array for studying cellular responses to orthogonal combinations of matrix and soluble signals. *Lab Chip*. 2010; 10:571. [PubMed: 20162232]
 234. Beske O, Goldbard S, Turpin P. The CellCard System: A novel approach to assessing compound selectivity for lead prioritization of G-protein-coupled receptors. *Comb Chem High Throughput Screen*. 2005; 8:293–299. [PubMed: 16101005]
 235. Fang C, Wang Y, Vu NT, Lin WY, Hsieh YT, Rubbi L, Phelps ME, Mueschen M, Kim YM, Chatziioannou AF, Tseng HR, Graeber TG. Integrated Microfluidic and Imaging Platform for a Kinase Activity Radioassay to Analyze Minute Patient Cancer Samples. *Cancer Res*. 2010; 70:8299–8308. [PubMed: 20837665]
 236. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. *N Engl J Med*. 2012; 366:883–892. [PubMed: 22397650]
 237. Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA, Kirby BJ. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. *Lab Chip*. 2010; 10:27–29. [PubMed: 20024046]
 238. Li P, Stratton ZS, Dao M, Ritz J, Huang TJ. Probing circulating tumor cells in microfluidics. *Lab Chip*. 2013; 13:602–609. [PubMed: 23306378]
 239. Nagrath S, Sequist L, Maheswaran S, Bell D, Irimia D, Ulkus L, Smith M, Kwak E, Digumarthy S, Muzikansky A. Isolation of rare circulating tumour cells in cancer patients by microchip technology. *Nature*. 2007; 450:1235–1239. [PubMed: 18097410]
 240. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. *Proc Natl Acad Sci USA*. 2010; 107:18392–18397. [PubMed: 20930119]
 241. Weigum SE, Floriano PN, Christodoulides N, McDevitt JT. Cell-based sensor for analysis of EGFR biomarker expression in oral cancer. *Lab Chip*. 2007; 7:995–1003. [PubMed: 17653341]
 242. Saliba AE, Saias L, Psychari E, Minc N, Simon D, Bidard FC, Mathiot C, Pierga JY, Fraissier V, Salamero J, Saada V, Farace F, Vielh P, Malaquin L, Viovy JL. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. *Proc Natl Acad Sci USA*. 2010; 107:14524–14529. [PubMed: 20679245]
 243. Spink B, Cole R, Katz B, Gierthy J, Bradley L, Spink D. Inhibition of MCF-7 breast cancer cell proliferation by MCF-10A breast epithelial cells in coculture. *Cell Biol Int*. 2006; 30:227–238. [PubMed: 16427788]
 244. Cukierman E, Pankov R, Yamada KM. Cell interactions with three-dimensional matrices. *Curr Opin Cell Biol*. 2002; 14:633–640. [PubMed: 12231360]
 245. Moschetta M, Pretto F, Berndt A, Galler K, Richter P, Bassi A, Oliva P, Micotti E, Valbusa G, Schwager K, Kaspar M, Trachsel E, Kosmehl H, Bani MR, Neri D, Giavazzi R. Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin-Positive Metastatic Human Melanoma Xenografts. *Cancer Res*. 2012; 72:1814–1824. [PubMed: 22392081]

Figure 1. Stages in the progression towards more relevant models in cell-based assays

The predictive value of drug development should theoretically improve when increasingly (*in vivo*) relevant models are used. This graph outlines some directions taken in cell culture development to improve these predictive values. Two parameters, cell type and culture system, are plotted in an x–y graph. The linear curve thereby explains the hypothetical increase in predictability of a cell culture system with the alteration of these parameters.

Along the x-axis, some examples of cell-types that have a higher relevance than cell lines in monoculture are plotted. This ranges from primary cells [87] to co-culture [243] to patient-derived materials [41], which is envisioned to be the most relevant model system. Systems that enable the culture and analysis of patient cells can be used for tailored treatment, which holds a high promise for the improvement of cancer therapy. On the y-axis, the culture platforms of different relevance are plotted. Depending on the model, a system with controlled extrinsic parameters may increase the relevance compared to standard 2D culture platforms [28, 244]. For example, long 2D patterns makes it possible to control cell growth of endothelial cells as capillary structures in 2D [26]. Platforms that enable 3D culture and recapitulate the organization of cells *in vivo* are probably amongst the most relevant [13, 33, 57, 87].

Figure 2. The role of the microenvironment in drug response and new treatment strategies

Factors present in the tumor microenvironment induce environment-mediated drug resistance (EMDR) by two primary mechanisms: soluble factor-mediated drug resistance (SFM-DR) and cell adhesion-mediated drug resistance (CAM-DR) (A). When the cancer is treated for the first time, most tumor cells respond to the drugs. However, the interaction with microenvironmental factors can give enough protective signaling for some of the cells to survive therapy and eventually to repopulate the tumor with resistant cells. Therefore, therapeutic strategies that disrupt EMDR pathways would reduce the level of surviving cells and prevent the emergence of acquired resistance [6, 15]. Cell adhesion via integrins is fundamental for cell survival, behavior and cell migration. Therefore, these receptors are central in the development of new tumor-stromal interaction disrupting drugs (B). Inhibiting specific integrins can reduce the effect of CAM-DR and block additional stromal processes such as angiogenesis [128–131] (left). On the other hand, the specific tumor microenvironment can also be used for targeted delivery of drugs by, for example, recognition of a cancer-specific fibronectin [245] (right).

Figure 3. Controlling microenvironmental parameters by microfabrication

Engineering on the single cell level makes it possible to control the cell microenvironment on many different levels. The controllable parameters include the ECM coating, cell spreading (cell shape), dimensionality and rigidity for an open microfabricated system (A). In a closed system (B), the liquid volume is controlled, and thereby the concentration of solutes and flow are additional parameters that can be controlled in such a system.

Figure 4. The application of miniaturized cell systems in cancer drug development

Different types of cell arrays can be useful to determine the effect and the interdependence of environmental parameters on drug response. (A) A PEG-hydrogel microwell array platform with protein only at the bottom of microwells is exploited to study the effect of cell-matrix interaction and cell-cell interaction in 3D cultured breast cancer cells. On this platform, the extrinsic parameters could be controlled to mimic the niche of a breast cancer. Further, confocal microscopy allowed insight into the role of cell positioning within the cluster and cell-density, comparing the images from different positions within the cluster (z_1 , z_2 and z_3). One result of this work was that not only cell-cell interactions are important in 3D drug response but also matrix-interaction, although its effect is spatially limited [62]. Multi-organ interaction can be studied on “body-on-a-chip” platforms (B), which represent an *in vitro* alternative to the animal or even patient customized human model, which can test the uptake, distribution and metabolic digestion of a drug in different organs. In one approach, a system was developed to integrate the effect of the intestinal absorption and the hepatic metabolism of drugs against breast cancer [221]. Miniaturized spotted adhesion arrays (C), with mixtures of different proteins, enables the combinatorial effect of different matrix proteins to be studied. By screening different combinations of fibronectin with other matrix proteins, it was found that the adhesion of one cell line was increased on fibronectin combined with collagen IV. The same study used the array to correlate ECM ligands to metastatic behavior [171]. Miniaturization enables the immediate capture and analysis of small cell samples from patients (D). The limited number of cells in patient samples has so far restricted their use in diagnosis and treatment prediction. However, the direct analysis of patient cells is an important aspect in enabling personalized treatment. In miniaturized systems, small cell numbers can be analyzed with a signal-to-noise ratio, which is similar to that in standard macro scale analysis of larger cell populations. In a versatile approach using self-assembly of magnetic beads decorated with antibodies, cells could not only be captured within a microsystem but also further cultured therein and analyzed [242].